

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

J. Bousquet, A Addis, I Adcock, I. Agache, A Agusti, A. Alonso, I Annesi-Maesano, J M Anto, C. Bachert, C E Baena-Cagnani, et al.

► To cite this version:

J. Bousquet, A Addis, I Adcock, I. Agache, A Agusti, et al.. Integrated care pathways for airway diseases (AIRWAYS-ICPs). European Respiratory Journal, 2014, 60, 10.1183/09031936.00014614 . hal-02565409

HAL Id: hal-02565409 https://hal.umontpellier.fr/hal-02565409v1

Submitted on 6 May 2020 $\,$

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

European Innovation Partnership on Active and Healthy Ageing, Action Plan B3 Mechanisms of the Development of Allergy (MeDALL, WP10) GARD (Global Alliance against Chronic Respiratory Diseases, WHO) research demonstration project

J. Bousquet¹⁻⁹, A. Addis^{7,10}, I. Adcock¹¹, I. Agache^{4,12,13}, A. Agusti¹⁴, A. Alonso¹⁵, I. Annesi-Maesano⁴, J.M. Anto^{3,14}, C. Bachert^{3,4,17,19}, C.E. Baena-Cagnani^{1,19}, C. Bai^{20,21}, A. Baigenzhin²², C. Barbar^{3/23}, P.J. Barnes¹¹, E.D. Batema^{4,24}, L. Beck²⁵, A. Bedbrook^{2,4}, E.H. Bel²⁴, O. Benezet², K.S. Bennoor^{4,27}, M. Benson²⁸, M. Bernabeu-Wittel^{27,30}, M. Bewick³¹, C. Bindslev-Jensen^{4,32}, H. Blain^{1,2,8}, F. Blasi³³, M. Bonini^{4,34}, S. Bonini^{4,35}, L.P. Boulet^{4,36}, A. Bourdin^{1,2,8,37}, R. Bourret^{1,2}, P.J. Bousquet⁴, C.E. Brightling³⁸, A. Briggs³⁹, J. Brozek^{4,40}, R. Buhl⁴¹, A. Bush^{4,42}, D. Caimm^{1,2,4}, M. Calderon^{43,44}, P. Calzola⁵⁰, A.M. Cepeda Sarabia^{4,51,52}, A. Cesario⁵³, Y.Z. Chen⁵⁴, E. Chkhartishvili⁵⁵, N.H. Chavannes^{4,36,37}, R. Chiron^{1,2,4}, A. Chuchalin^{4,88,59}, K.F. Chung¹¹, L. Cox^{4,40}, G. Crooks⁴¹, M.G. Crooks⁴², A.A. Cruz^{4,88,43}, A. Custovic^{4,5,44}, R. Dahl^{4,32}, S.E. Dahlen⁴⁵, F. De Blay^{4,66,7}, T. Dedeu⁴⁵, D. Deleanu^{4,12,49}, P. Demoly^{1,2,4,5,74}, P. Devillie^{r,1,72}, A.T. Dinh-Xuan⁷³, R. Djukanovic⁷⁴, D. Dokic^{4,75}, H. Douagul^{4,75}, R. Dubakiene^{4,77,78}, S. Eglin⁷⁹, F. Elliof⁴⁰, R. Emuzyte^{4,77,78}, L. Eabhr⁴¹, A. Fink Wagne^{42,75}, H. Fletcher^{38,33}, W.J. Fokkens^{4,26,44}, J. Fonsca^{4,23,85,86}, A. Franco⁵⁷, P. Frith⁸⁸, A. Furber⁸⁹, M. Gaga³⁰, J. Garcé^{51,32}, J. Garcia-Aymerich^{3,16}, A. Gamkrelidz^{4,53}, S. Gonzales-Diaz^{4,32}, F. Gouzi^{1,37}, M.A. Guzmán^{4,54}, H. Humbert⁷¹, M. Hyland¹⁰⁰, G. Iaccarino¹⁰¹⁻¹⁰³, D. Jakovenko², J.R. Jardim¹⁰⁴, C. Jeandel^{1,2,8}, C. Jenkin¹⁰⁵, S.L. Johnston^{4,158}, V. Kolek¹¹³, M.L. Kowalski¹¹⁴, I. Kull^{3,115}, P. Kuna^{4,75,8,116,117}, V. Kvedariene^{4,5,77,118}, L.T. Le^{4,58,119}, N. Khaltaev^{4,58}, V. Kolek¹¹³, M.L. Kowalski¹¹⁴, I. Kull^{3,115}, P. Kuna^{4,75,8,116,117}, V. Kvedariene^{4,5,77,118}, L.T. Le^{4,58,119}, N. Khaltaev^{4,58}, V. Kolek¹¹³, M.L. Kowalski¹¹⁴, J. Kull^{3,115}, P. Kuna^{4,75,8,116,117}, V. Kvedariene^{4,5}

ABSTRACT The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patients, using a common strategy; 4) having a significant impact on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long-term (healthy ageing); 5) proposing a common simulation tool to assist physicians; and 6) ultimately reducing the healthcare burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life. In the longer term, the incidence of disease may be reduced by innovative prevention strategies. AIRWAYS-ICPs was initiated by Area 5 of the Action Plan B3 of the European Innovation Partnership on Active and Healthy Ageing. All stakeholders are involved (health and social care, patients, and policy makers).

Affiliations: ¹University Hospital Montpellier, Montpellier, France. ²MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France. ³MeDALL, Mechanisms of the Development of Allergy. 4ARIA, Allergic Rhinitis and Its Impact on Asthma. 5EAACI, European Academy of Allergy and Clinical Immunology. ⁶EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site. ⁷EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action. ⁸UM1, University 1, Montpellier, France. ⁹Fondation Partenariale, France. ¹⁰EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Regione Emilia-Romagna, Italy. "National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK. ¹²Romanian Alliance Against Chronic Respiratory Diseases. ¹³Faculty of Medicine, Transylvania University, Brasov, Romania. ¹⁴Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias, Barcelona, Spain. ¹⁵Hospital Clínic/FCRB, Barcelona, Spain. ¹⁶Centre for Research in Environmental Epidemiology (CREAL), IMIM (Hospital del Mar Medical Research Institute, Universitat Pompeu Fabra (UPF), CIBER Epidemiology (CREAL), MMM (Hospitat det Mar Medicat Research Institute, Universitat Pompeu Fabra (UPF), CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. ¹⁷Dept Respiratory Medicine, Ghent University Hospital, Gent, Belgium. ¹⁸ENT Dept, Ghent University Hospital, Gent, Belgium. ¹⁹Research Centre in Respiratory Medicine (CIMER), Faculty of Medicine, Catholic University, Cordoba, Argentina. ²⁰Shanghai Respiratory Research Institute, Chinese Medical Association, Shanghai, China. ²¹Chinese Alliance against Lung Cancer. ²²EuroAsian Respiratory Society, Astana City, Kazakhstan. ²³PNDR, Portuguese National Programme for Respiratory Diseases. ²⁴Division of Pulmonology, Dept of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa. ²⁵Health Innovation Centre of Southern Denmark, Region of Southern Denmark, Denmark, ²⁶Academic Medical Centre, University of Amsterdam, The Netherlands. ²⁷Bangladesh Lung Foundation and National Institute of Diseases of Chest and Hospital, Dhaka, Bangladesh. 28 Centre for Individualised Medicine, Dept of Clinical and Experimental Sciences, Linköping University, Linköping, Sweden. ²⁹EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Aura Andalucia, Spain. ³⁰Andalusian Healthcare Service, Spain. ³¹Deputy National Medical Director, NHS England, UK. ³²Dept of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, Odense, Denmark. ³³ERS, European Respiratory Society, University of Milan, IRCCS Cà Granda, Milan, Italy. ³⁴Dept of Public Health and Infectious Diseases 'Sapienza' University of Rome, Rome, Italy. ³⁵Second University of Naples and Institute of Translational Medicine, Italian National Research Council, Naples, Italy. ³⁶Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec City, QC, Canada. ³⁷INSERM, U1046, Montpellier, France. ³⁸National Institute for Health Research, Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK. ³⁹Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK. ⁴⁰Depts of Clinical Epidemiology, and Biostatistics and Medicine, McMaster University, Hamilton, ON, Canada. ⁴¹Pulmonary Dept, III, Medical Centre, Mainz University Hospital, Mainz, Germany. ⁴²Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK. ⁴³University of Costa Rica, San Jose, Costa Rica. ⁴⁴Section of Allergy and Clinical Immunology, Imperial College London, Royal Brompton Hospital, London, UK. ⁴⁵Institute of Ageing and Chronic Disease, University of Liverpool and University Hospital Aintree, Liverpool, UK. ⁴⁶Dept of Pediatrics, Medical School, Federal University of Minas Gerais, Belo Horizonte, Brazil. ⁴⁷Allergy and Respiratory Diseases, IRCCS San Martino - IST- University of Genoa, Dept of Internal Medicine, Genoa, Italy. ⁴⁸NAH, National Allergy Health Programme, Norway. ⁴⁹University of Oslo and Oslo University Hospital, Dept of Paediatrics, Oslo, Norway. ⁵⁰University of Rome "Tor Vergata" Dept of System Medicine, Rome, Italy. ⁵¹Allergy and Immunology Laboratory, Metropolitan University, Simon Bolivar University, Barranquilla, Colombia. ⁵²SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia. ⁵³IRCCS, San Raffaele Pisana, Rome, Italy. ⁵⁴National Cooperative Group of Paediatric Research on Asthma, Asthma Clinic and Education Center of the Capital Institute of Pediatrics, Peking and Center for Asthma Research and Education, Beijing, PR China. 55 Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Grigol Robakidze University, Tbilisi, Georgia. ⁵⁶IPCRG, International Primary Care Respiratory Group. ⁵⁷Dept of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands. 58 GARD, Global Alliance against Chronic Respiratory Diseases (WHO). ⁵⁹Pulmonology Research Institute and Russian Respiratory Society, Moscow, Russia. ⁶⁰Nova Southeastern University Osteopathic College of Medicine, Davie, FL, USA. ⁶¹EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, NHS Scotland, Glasgow, UK. ⁶²Centre for Cardiovascular and Metabolic Research, Hull York Medical School, Hull, UK. ⁶³ProAR, Nucleo de Excelencia em Asma, Federal University of Bahia and CNPq, Salvador, Brazil. ⁶⁴University of Manchester, Manchester, UK. ⁶⁵CfA, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden. ⁶⁶SFA, Société française d'Allergologie. ⁶⁷Strasbourg University, Strasbourg, France. ⁴⁸EUREGHA, European Regions and Health Authorities, Brussels, Belgium. ⁴⁹University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania. 70 UPRES, EA 220, Université Versailles Saint Quentin, Hôpital Foch, Suresnes, France. ⁷¹SPLF, Société de Pneumologie de Langue Française. ⁷²Dept of Respiratory Medicine, University of Toulouse, Toulouse, France. ⁷³Service de Physiologie, Paris Descartes University EA 2511, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, Paris, France. ⁷⁴University Southampton Faculty of Medicine and NIHR Southampton Respiratory Biomedical Research Unit, Southampton, UK. ⁷⁵University Clinic of Pulmology and Allergy, University "Ss. Cyril and Methodius", Skopje, Macedonia. ⁷⁶Service de pneumo-allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria. ⁷⁷LSACI, Lithuanian Society of Allergology and Clinical Immunology. ⁷⁸Vilnius University Faculty of Medicine, Vilnius, Lithuania. ⁷⁹NHS R&D North West, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, UK. ⁸⁰EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, NHS Scotland, Edinburgh, UK. 81Dept of Oncology, Haematology and Respiratory Diseases, Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy. ⁸²GAAPP, Global Allergy and Asthma Patient Platform, Vienna, Austria. ⁸³Education for Health, Warwick, UK. ⁸⁴European Rhinology Society. ⁸⁵Porto Age-Up Consortium, Porto, Portugal. 86 Dept of Health Information and Decision Sciences and CINTESIS, Porto University Medical School, Allergy, Hospital S. Joao and Instituto and Hospital CUF Porto, Porto, Portugal. ⁸⁷Internal and Geriatric Medicine, University of Nice - Sophia Antipolis, Nice, France. ⁸⁸Repatriation General Hospital, Adelaide, Australia. ⁸⁹Director of Public Health, Wakefield Council, Wakefield, UK. ⁹⁰7th Respiratory Medicine Dept and

Asthma Centre, Athens Chest Hospital, Athens, Greece. 91EIP on AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Valencia, Spain. ⁹²Polibienestar Research Institute, University of ³National Center for Disease Control and Public Health of Georgia, Tbilisi, Georgia. Valencia, Valencia, Spain. ⁹⁴Immunology and Allergology Division, Dept of Medicine, Clinical Hospital University of Chile, Santiago, Chile. ⁹⁵Dept of Allergy, Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland. ⁹⁶Director of Public Health for Blackburn with Darwen, Blackburn, UK. 97 Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK. ⁹⁸Dept of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Leuven, Belgium. ⁹⁹Director of Public Health for Kirklees, Huddersfield, UK. ¹⁰⁰School of Psychology, University of Plymouth, Plymouth, UK. ¹⁰¹EIP on AHA Reference Site, Regione-Campania, Italy. ¹⁰²Dept of Medicine and Surgery, University of Salerno, Salerno, Italy. ¹⁰³IRCCS Multimedica, Milan, Italy. ¹⁰⁴Respiratory Diseases, Escola Paulista de Medicina of Federal University of Sao Paulo, Sao Paulo, Brazil. ¹⁰⁵The George Institute for Global Health and The University of Sydney, Sydney, Australia. 106 Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, London, UK. ¹⁰⁷Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Gyeonggi-do, South Korea. ¹⁰⁸GARD-Turkey, Global Alliance against Chronic Respiratory Diseases (GARD), Turkey. ¹⁰⁹Hacettepe University School of Medicine, Paediatric Allergy and Asthma Unit, Hacettepe, Ankara, Turkey. ¹¹⁰Director of Public Health, Lancashire, UK. ¹¹¹Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany. ¹¹²Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany. ¹¹³CARO, Czech Alliance against Chronic Respiratory Diseases. ¹¹⁴Dept Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Lodz, Poland. ¹¹⁵Karolinska Institutet, Dept of Clinical Science and Education, Institute of Environmental Medicine, Stockholm, Sweden. ¹¹⁶Polastma, Poland. ¹¹⁷Dept of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland. 118 Pulmonology and Allergology Center, Vilnius University, Vilnius, Lithuania. ¹¹⁹University of Medicine and Pharmacy, Hochiminh City, Vietnam. ¹²⁰CHU Liege, GIGA 1³ Research Center, University of Liege, Liege, Belgium. ¹²¹Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK. ¹²²Directorate of Finance, eHealth and Pharmaceuticals, Scottish Government Health Dept, Edinburgh, UK. ¹²³University of Bratislava, Bratislava, Slovakia. ¹²⁴Dept of Medicine, Royal College of Surgeons in Ireland (Medical School) Bon Secours Hospital, Dublin, Ireland, ¹²⁵Kronikgune, Basque Region, Spain. ¹²⁶Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran. ¹²⁷Royal Brompton Hospital, London, UK. ¹²⁸Geneva Medical School and University Hospitals, Geneva, Switzerland. ¹²⁹University Hospital for Pulmonary Diseases, Jordanovac, Zagreb, Croatia. ¹³⁰Institute of Pneumology Marius Nasta, Bucharest, Romania. ¹³¹Faculty of Medicine, University of Belgrade, Belgrade, Serbia. ¹³²Serbian Alliance against Chronic Respiratory Diseases. ¹³³Association for Asthma and COPD in Serbia. ¹³⁴Bordeaux University, Bordeaux, France. ¹³⁵Paris Descartes University, Dept of Public Health and Biostatistics, EA 4064 and Paris Municipal, Dept of Social Action, Childhood and Health, Paris, France. ¹³⁶Immunoallergy Dept, Hospital CUF-Descobertas, Lisbon, Portugal. ¹³⁷SPAIC, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal. ¹³⁸Respiratory National Clinical Director, NHS England, UK. ¹³⁹Service de Médecine Interne et Pathologies Professionnelles, Hôpital Polyclinique de Dakar (IHS), Dakar, Sénégal. ¹⁴⁰Mustapha Hospital, Algiers, Algeria. ¹⁴¹Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary. ¹⁴²GA²LEN, Global Allergy and Asthma European Network. ¹⁴³Charité University Hospital, Allergy Centre Charité, Berlin, Germany. ¹⁴⁴Service de Pneumologie, 1011 CHUV-Lausanne, Lausanne, Switerland. ¹⁴⁵Dept of Allergy, Immunology and Respiratory Madicine. Alfred Hospital and Manach Liniversity. Molhoure Australia. ¹⁴⁶Netional Hospital Agentic. Medicine, Alfred Hospital and Monash University, Melbourne, Australia. ¹⁴⁶National Hospital Organization, Tokyo National Hospital and Teikyo University School of Medicine, Tokyo, Japan. ¹⁴⁷Cardio-Thoracic and Vascular Dept, University Hospital of Pisa, Pisa, Italy.¹⁴⁸EFA, European Federation of Allergy and Airways Diseases patients' association.¹⁴⁹Centre for Reviews and Dissemination (CRD), University of York, York, UK. ¹⁵⁰Allergy Dept, 2nd Paediatric Clinic, University of Athens, Athens, Greece. ¹⁵¹Ferrara University, Ferrara, Italy. ¹⁵²NDM Research Building, University of Oxford, Oxford, UK. ¹⁵³SPLF, Espace francophone de Pneumologie. ¹⁵⁴Children's Hospital Srebrnjak, Zagreb, School of Medicine, University J.J. Strossmayer, Osijek, Croatia. ¹⁵⁵University of Groningen, Dept of Pulmonology, GRIAC Research Institute University Medical Center Groningen, Groningen, The Netherlands. ¹⁵⁶Academic Primary Care, University of Aberdeen, Aberdeen, UK. ¹⁵⁷Christian Albrechts University Kiel, LungenClinic Grosshansdorf, Airway Research Center North (ARCN), German Center for Lung Research (DZL), Germany. ¹⁵⁸Research Institute INCLIVA, University of Valencia, CIBERObn, Health Institute Carlos III, Madrid, Spain. ¹⁵⁹University of Nebraska Medical Center, Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha, NE, USA. ¹⁶⁰Respiratory Nurse Consultant, Salford Royal NHS Foundation Trust, Salford, UK. ¹⁶¹INSERM, U710 and 988, Montpellier, France. ¹⁶²Pneumologie, AP-HP, Hôpital Cochin - Site Val de Grâce, Université Paris Descartes and SPLF, Société de Pneumologie de Langue Française, Paris, France. ¹⁶³Arcispedale, S.Maria Nuova Hospital, Reggio Emilia, Italy. ¹⁶⁴Association Asthme et Allergies, Boulogne-Billancourt, France. ¹⁶⁵Woodbrook Medical Centre, Loughborough, UK. ¹⁶⁶Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Edinburgh, UK. ¹⁶⁷Dept of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland. ¹⁶⁸Dept of Allergy and Clinical Immunology, Centro Medico-Docente La Trinidad, Caracas, Venezuela. ¹⁶⁹Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA.¹⁷⁰Child Health, Queen's University Belfast and Royal Belfast Hospital for Sick Children, Belfast, UK.¹⁷¹Dept of Thoracic Medicine, University Hospital of Heraklion, Heraklion, Greece.¹⁷²University Hospital of Mont-Godinne, Catholic University of Louvain, Yvoir, Belgium. ¹⁷³Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", Paris, France. ¹⁷⁴INSERM, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", Paris, France. ¹⁷⁵AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département "R3S"), Paris, France. ¹⁷⁶Fonds de Dotation Recherche en Santé Respiratoire - Fondation du Souffle, Paris, France. ¹⁷⁷National Advisory Group, Respiratory Managed Clinical Networks in Scotland. 178HITT, Health Institute for Technology Transfer, Barcelona, Spain. ¹⁷⁹EuroAsian Respiratory Society, Bishkek, Kyrgyzstan. ¹⁸⁰National Centre Cardiology and Internal Medicine, Bishkek, Kyrgyzstan. ¹⁸¹Pulmonary Division, InCor (Heart Institute), Hospital da Clinicas da

Faculdade de Medicina da Universidade de Sao Paulo, Sao Paulo, Brazil. ¹⁸²Dept of Neonatal Intensive Care, Oslo University Hospital, Ulleval, Faculty of Medicine, University of Oslo, Oslo, Norway. 183 European Academy of Paediatrics (EAP-UEMS). ¹⁸⁴Regional Medical Manager (North), NHS England, UK. ¹⁸⁵Observatoire wallon de la santé, Direction générale opérationnelle Pouvoirs locaux, action sociale et Santé, Service public de Wallonie, Belgium. ¹⁸⁶Immunoallergy Dept, Coimbra University Hospital, Coimbra, Portugal. ¹⁸⁷Dept of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectology and Immunology, Medical University of Vienna, Vienna, Austria. 188LACRD, Lithuanian National Alliance Against Chronic Respiratory Diseases. 189Dept of Lung Diseases and Clinical Allergology, University of Turku, Finland. ¹⁹⁰Pharmacoepidemiology Unit and Respiratory Medicine, CHU-Lyon and UMR CNRS 5558, Claude-Bernard University Lyon, Lyon, France. ¹⁹¹FILHA, Finnish Lung Association. ¹⁹²Respiratory and Allergy Research Group, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK. ¹⁹³Dept of Respiratory Medicine J, Odense University Hospital, Odense, Denmark. ¹⁹⁴EIP on AHA B3 Action Group (Delivering Integrated Care Models), Regional Agency for Health and Social Care, Arcispedale S.Maria Nuova/IRCCS, Research Hospital, Reggio Emilia, Italy. ¹⁹⁵CNR, Institutes of Biomedicine and Molecular Immunology (IBIM), Palermo, and of Clinical Physiology (IFC), Pisa, Italy. ¹⁹⁶German Center for Lung Research (DZL), Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany. 197Sotiria Hospital, Athens, Greece. ¹⁹⁸Acting Director of Public Health, Cumbria County Council, Carlisle, UK. ¹⁹⁹Hôpital Albert Calmette, CHRU, Lille, France. 200 Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA. ²⁰¹North of England EU Health Partnership, UK. ²⁰²Olmsted Medical Center, Dept of Research and University of Minnesota, Dept of Family and Community Health, Rochester, MN, USA. 203 Cyprus International Institute for Environmental and Public Health in Association with Harvard School of Public Health, Cyprus University of Technology, Limassol, Cyprus. 204The Allergy and Asthma Institute, Pakistan. 205Dept of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, Cape Town, South Africa. ²⁰⁶Guangzhou Institute of Respiratory Diseases and State Key Laboratory of Respiratory Diseases, Guangzhou Medical College, Guangzhou, China. 207 University Clinic of Respiratory and Allergic Diseases, Golnik, Slovenia.

Correspondence: A. Bedbrook, MACVIA-ARIA, Hopital Arnaud de Villeneuve, Service Maladies Respiratoires, 34295 Montpellier, France. E-mail: anna.bedbrook@inserm.fr

Introduction

Chronic respiratory diseases: from guidelines to policies

Chronic respiratory diseases are major non-communicable diseases [1]. Asthma and allergic diseases occur throughout the life cycle and can begin during pregnancy and childhood. In Europe, they affect 30 million children and adults under 45 years of age. Chronic obstructive pulmonary disease (COPD) has an estimated annual death rate of over 4 million people globally. Among the European Union (EU) member states, asthma accounted for an average of 53 hospital admissions per 100 000 population in 2009, and the average COPD-related admission rate was 184 [2]. The annual direct and indirect costs in the 28 EU countries due to COPD or asthma are estimated at €48 billion and €34 billion, respectively [2]. Chronic respiratory diseases affect active and healthy ageing. Asthma in children or adults is a common risk factor for COPD in adults [3, 4].

Guidelines for COPD [5] and rhinitis–asthma comorbidity [6] exist using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach [7, 8]. Global strategies have also been proposed for the prevention and control of asthma [9] and COPD [10]. However, in older adults, it is often difficult to differentiate between asthma and COPD [11], and none of the current guidelines appear to have a specific module for older people [12].

Effective strategies are needed to reduce chronic respiratory disease burden. National programmes (*e.g.* the Finnish, Czech or Portuguese asthma or COPD programmes [13, 14]) can be cost-effective [15], but they are insufficiently implemented in the EU. Integrated care pathways (ICPs) for COPD (QS10) exist in the UK (National Institute for Health and Care Excellence, NICE) [16], in France (Haute Autorité de Santé) and in the Netherlands [17–19], but ICPs for asthma or asthma and rhinitis comorbidity do not exist. Asthma quality standards for asthma (QS25) have been published by NICE [20]. These are specific, concise statements that act as markers of high-quality, cost-effective patient care. Moreover, some initiatives are aimed at also incentivising good practice and improving implementation (*i.e.* remuneration based on performance indicators). In the UK, the Quality and Outcomes Framework has four asthma-specific performance indicators which are explicitly linked to the subsequent remuneration of providers [21].

Support statement: The study was funded by Région Languedoc-Roussillon.

In low-resource settings, some successful attempts to combine all non-communicable diseases into one single action plan have been developed [22–24] for the implementation of the World Health Organization (WHO) non-communicable disease action plan. However, such combined plans are not available for the management of non-communicable diseases in high-resource settings.

The Polish Presidency of the EU Council (3051st Council Conclusions) has made the prevention, early diagnosis and treatment of asthma and allergic diseases a priority to reduce health inequalities [25, 26]. The 3206th Cyprus Council Conclusions recommended that the diagnosis and treatment of chronic diseases should be initiated as early as possible to improve active and healthy ageing [27]. A debate at the European Parliament (Cyprus Presidency of the EU Council, 2012) recommended early diagnosis and management of chronic respiratory diseases in children in order to promote active and healthy ageing [28].

Protective and risk factors

Chronic respiratory diseases and other non-communicable diseases often share environmental risk factors (*e.g.* tobacco, nutrition, indoor and outdoor air pollution, and sedentary lifestyle) [1, 29], leading to sustained local and systemic inflammation [30, 31] and impaired ageing. Tobacco smoking is the best-identified risk factor for many non-communicable diseases, including chronic respiratory disease.

The prevention and control of chronic diseases could be considered sequentially before the disease has been identified in order to 1) prevent its onset (health promotion and primary prevention), and 2) better control and prevent the short- and long-term consequences after its onset (secondary and tertiary prevention and control).

Starting in early childhood, the foundations for healthy or weakened respiratory organs are laid from a political perspective to feed into the goals of the Europe 2020 strategy as well as healthy and active ageing [32]. Multi-sectoral prevention, including policy change, regulation and market intervention, is of the highest priority.

Integrated care pathways

ICPs, also known as clinical pathways or care pathways, are structured multidisciplinary care plans which detail essential steps in the care of patients with a specific clinical problem [33]. They promote the translation of guidelines into local protocols and their subsequent application to clinical practice. An ICP forms all or part of the clinical record, documents the care given, and facilitates the evaluation of outcomes for continuous quality improvement [34]. ICPs empower patients as well as their health and social carers.

ICPs differ from practice guidelines as they are utilised by a multidisciplinary team, and focus on the quality and co-ordination of care. ICPs need to record variations from planned care [35]. An ICP is intended to inform and encourage thought and adaptation. Clinicians are free to exert their own professional judgments as appropriate. However, any alteration to the practice identified within the ICP must be noted as a variance [36]. Variance analysis may be used to optimise the ICPs linked with pay-for-performance [37–40], audit and feedback, and integration of recommendations with electronic medical records.

ICPs are already the standard of care in different areas of medicine, such as oncology [41] or palliative care [42]. Some have already been proposed for asthma or COPD.

The care pathways simulator, a discrete event simulation software programme, helps to view the system from the perspective of the task, job or patient, rather than of the function [43]. Service redesign, targeted at improving services, can bring benefit to patients, carers, staff and National Health Service (NHS) trusts [44].

European Innovation Partnership on Active and Healthy Ageing

European innovation partnerships attempt to enhance EU competitiveness and to tackle societal challenges by fostering innovation. They address the weaknesses in EU research and innovation that complicate the discovery or exploitation of knowledge and may hinder innovation into the market place.

Active and healthy ageing is a major societal challenge common to all countries and to all populations [45]. Ageing is intertwined with socioeconomic inequalities [46], is an under-appreciated cause of poverty and hinders economic development, particularly affecting underserved populations and females. Active and healthy ageing needs to be promoted very early in life to be successful.

The European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) is deployed in three areas and six action plans [47]:

- Prevention of diseases and health promotion
 - Innovative ways to ensure that patients adhere to their treatments (A1)
 - Innovative solutions for personalised health management, with focus on falls prevention (A2)
 - Action for preventing functional decline and frailty, with a particular focus on malnutrition (A3)
- Care and cure: scaling up and replication of successful innovative integrated care models for chronic diseases among older patients, such as through remote monitoring (B3)
- Active and independent living of older adults by improving the uptake of interoperable independent living solutions including guidelines for business models (C2)
- Horizontal topics: networking and knowledge sharing on innovation for age-friendly environments (D4)

The EIP on AHA aims to provide a framework for supporting bottom-up innovations and a forum for professional collaboration. The partners work on a voluntary basis to pool their knowledge and expertise in order to deploy, scale-up and replicate innovative health and care services.

The implementation of the strategy and action plan of WHO Europe on healthy ageing [48] has synergies with a number of the priorities and actions identified in the strategic implementation plan of the EIP on AHA, and shares its positive vision of ageing.

Objectives of AIRWAYS-ICPs

The general objective of AIRWAYS-ICPs is to develop multi-sectoral ICPs for CRDs used across European countries and regions in order to 1) reduce the burden of the diseases, 2) promote active and healthy ageing, and 3) create a care pathways simulator tool which can be applied in older adults. AIRWAYS-ICPs will not duplicate existing EU prevention programmes in chronic respiratory diseases (*e.g.* anti-smoking) but will strengthen them where appropriate.


The aim of AIRWAYS-ICPs is to propose central unifying themes and an overall potential to gain political leverage in the current environment and to better understand and manage the spectrum of care for patients with chronic airway disease in European countries and regions. It will also aim to generalise the approach to the uniform definition of severity, control and risk of severe asthma presented to the WHO [49], as well as of allergic diseases [50], in order to develop a uniform risk stratification usable for chronic respiratory diseases in most situations.

AIRWAYS-ICPs will propose a feasible, achievable and manageable project from science to guidelines (fig. 1) using existing networks and partners committed to Action Plan B3 of the EIP on AHA.

Specific objectives include the following:

1) To collect guidelines and ICPs that exist in European countries and regions for airway diseases (asthma, COPD and rhinitis).

- 2) To strengthen prevention and health promotion for airway diseases.
- 3) To stratify patients with severe chronic respiratory diseases.
- 4) To understand AIRWAY diseases in children and adolescents and to develop ICPs (P.A.R.IS).



5) To develop important questions on chronic respiratory diseases for older people.

6) To understand and overcome barriers in chronic respiratory disease management.

7) To develop ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD and asthma in older people, combining preventive and disease control strategies based on existing national (or regional) programmes (*e.g.* Finnish or Portuguese asthma, COPD and allergy programmes).

8) To develop a simulation tool of ICPs for rhinitis and asthma comorbidity that could be applied to older people and to redesigning care pathways.

9) To tackle chronic respiratory diseases across the life cycle, placing a particular interest in the cultural and social aspects of the diseases in a project centred on the patient.

10) To implement multi-sectoral, multi-country initiatives to allow the practical use of AIRWAYS-ICPs by European countries and regions, and beyond to other countries, for cost-effective policies on the prevention and control of asthma, COPD and allergy.

AIRWAYS-ICPs working group

The AIRWAYS-ICPs working group has included the WHO Global Alliance against Chronic Respiratory Diseases and WHO Collaborating Center (2001–2013) working groups (64 countries). Moreover, we have attempted to include as many European countries as possible (23 EU countries) and it should be noted that Serbia, Croatia, Slovenia and Slovakia, who were not included in the previous study groups, are now included with a large number of representatives. Moreover, we have enhanced the study group by including social carers and public health researchers. Patients are well represented. In some countries, the names of the representatives have been proposed by governmental organisations. Finally, through the EIP on AHA, European Regions and Health Authorities (EUREGHA), other representatives were included, in particular NHS England, Scotland and Northern Ireland, as well as Wallonie and Southern Denmark. The working group now includes all the stakeholders required for the development of multi-sectoral ICPs.

AIRWAYS-ICPs

1) To collate existing ICPs, national programmes and guidelines

Tools used in the 28 EU countries and other European countries will be collected with regards to ICPs for COPD, asthma and rhinitis. This approach will be deployed to other countries. A repository is being developed by the EIP on AHA to collect projects such as:

1) Good practices of the B3 Action Group on integrated care.

2) The Finnish plans for asthma [13], allergy [51] and COPD [14] which are considered to be the prototypes of national plans for chronic respiratory diseases. Polastma (Poland) is, in particular, derived from the asthma plan.

3) The Portuguese National Programme for Respiratory Diseases (PNDR), the first national programme to include all respiratory diseases.

4) Care pathways provided by national institutions (e.g. NICE in the UK or the Haute Autorité de Santé in France).

5) The WHO guidelines for asthma and COPD in low-income settings.

6) A common approach to severe asthma and allergic diseases.

7) International Primary Care Respiratory Group mapping of national guidelines used by primary care for COPD, asthma, rhinitis, community-acquired pneumonia, obstructive sleep apnoea and smoking cessation [52].

2) To strengthen EU policies for the prevention of chronic respiratory diseases

The European Commission addresses chronic respiratory disease as a key priority and includes legislation on tobacco consumption and ambient air quality, work on climate change, and actions under the European Environment and Health Strategy. These policies tie in with active Commission support for the current United Nations process to address non-communicable diseases and related socioeconomic and environmental determinants. There is an urgent need to strengthen prevention and health promotion, in particular for smoking cessation ("Health for Growth" public health programme), improved physical and social environment, and promotion of lifestyle of beneficial value for "whole of society" and "vulnerable groups" in particular [53].




FIGURE 2 Decision-making steps for the stratification of severe allergic disease, with correlating action steps for management. Reproduced from [50] with permission from the publisher.

3) Stratification of patients with severe chronic respiratory diseases

Severity is the intrinsic severity of the disease process, control is the degree to which therapy goals are met, and responsiveness is the ease with which control is achieved by therapy. The concept of severity and control has been largely developed for asthma in guidelines [54]. The uniform definition of severe asthma [55] presented to the WHO [49] used an approach derived from the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines [56]. This approach has also been used for all allergic diseases (fig. 2) [50] and may be used for COPD (table 1).

The stratification of patients with chronic respiratory diseases can be generalised using the approach of the uniform definition of severe asthma presented to the WHO [55], in order to have a uniform definition of severity, control and risk usable in most situations. This uniform definition will make it possible to better define the phenotypes of severe allergic (and related) diseases for clinical practice, research (including epidemiology), public health purposes and the development of novel therapies targeted to better defined phenotypes.

4) Understanding airway diseases in children and adolescents and developing ICPs (P.A.R.IS)

Allergic diseases and asthma often start early in life, and most patients will have developed disease before the age of 18 years. It is therefore important to understand the risk factors and mechanisms underlying allergic chronic respiratory diseases and asthma in childhood, as well as to determine the gaps in the management of these diseases in preschool children, school children and adolescents. The prevention of early diagnosis and the management of chronic respiratory diseases in children is vital for the improvement of active and healthy ageing.

Within the framework of the EIP on AHA, the European Academy of Allergy and Clinical Immunology (EAACI) has decided, in collaboration with Allergic Rhinitis and its Impact on Asthma (ARIA), to develop a programme to better understand AIRWAY diseases in children and to propose a framework for the development of ICPs in this age group, considering rhinitis and asthma as a single entity.

The Allergy Sentinel Network, approved by the European Parliament, will be developed in Paris [28].

5) Development of important questions on chronic respiratory diseases for older people

Clinically important questions on the diagnosis and management of chronic respiratory diseases in older adults will be defined using a three-step Delphi process. The questions include COPD, asthma, rhinitis and chronic respiratory disease comorbidities. Multi-sectoral experts and patients are included.

	Asthma	COPD
Underdiagnosis	Common	Extremely common
	If asthma is not diagnosed, severe exacerbations can occur	Patients usually consult when they have (very) severe disease or an exacerbation
	Asthma deaths mostly occur in untreated patients In occupational asthma, early diagnosis is needed	If diagnosed earlier, smoking cessation measure could be initiated and prevent the worsening COPD and comorbidities
Effective treatment		
Preventive treatment	Asthma prevention is not effective, except in some cases, such as occupational asthma	Smoking cessation effective (at least when started early)
Drugs	Inhaled corticosteroids and β_2 -agonists very effective on symptoms and control	Somewhat effective on symptoms High variability due to different COPD phenotype
	At regular doses, no treatment is clearly effective on remodelling	(e.g. chronic bronchitis and emphysema) Modestly effective on exacerbations, possibly because phenotypes are not well characterise and COPD encompasses several different phenotypes which may respond differently to drugs
		No treatment effective on decline of lung function
Treatment availability and affordability	A global problem	
Differential diagnosis	Many "uncontrolled" patients with current asthma medications have asthma and another disease or another disease (<i>e.g.</i> bronchiectasis)	Many COPD patients have a differential diagnosi (including lung cancer)
Compliance and literacy	For drugs	For smoking cessation
Inhaler misuse	A global	problem
Smoking and other risk factors	A global problem	
Comorbidities	Severe nasal problems (e.g. polyposis) may impair asthma control	Key problem: many patients with COPD have severe comorbidities that may not even be diagnosed
Mand downsation and social second	Many deaths are due to comorbidities	
Mood, depression and socioeconomic status	A global problem	
Controlled disease with high intensity treatment	A large number of patients fall into this category If treatment is stopped, exacerbations can occur quickly	Phenotypes are not well characterised and COP encompasses several different diseases (e.g. chronic bronchitis and emphysema) that may respond differently to drugs Phenotypic characterisation is urgently needed

First Delphi round: experts were asked to propose the three major problems they would like to have answered concerning disease in older people, including comorbidities.

Second Delphi round: the questions were assessed by a group of four experts (two methodologists) to check for redundancy among the questions proposed (similar wording).

Third Delphi round: the questions were sent to the group for agreement.

Fourth Delphi round: the harmonised questions will be sent to 60 experts who will rank them.

The prioritised questions include: 1) asthma in older people; 2) COPD in older people; 3) rhinitis in older people; 4) comorbidities of asthma and COPD in older people; and 5) how paediatric interventions have an impact on ageing associated with respiratory diseases.

The list of questions will also be customised in order to be applicable to all countries and targeted to low, middle and high-income settings within which socioeconomic and health problems differ. The third Delphi round will be reviewed by two expert panels: one from developing countries and another from developed countries.

The prioritised questions will be answered after a review of available evidence using the GRADE approach.

Further to the first completed steps, it was felt that a better definition was needed for airway diseases and how they cluster in comorbidities (respiratory and non-respiratory). There are likely to be differences within the life cycle.




FIGURE 3 Development of integrated care pathways (ICPs).

6) Understanding and overcoming barriers in chronic respiratory disease management Many barriers exist and prevent the deployment and use of a non-communicable disease global approach in different settings and countries.

7) Development of ICPs for rhinitis and asthma comorbidity across the life cycle, and for COPD, asthma and comorbidities in older people

1) To develop multi-sectoral ICPs which can be used across Europe and in other countries.

2) For asthma and rhinitis comorbidity, the P.A.R.IS approach (EAACI–ARIA) will be used in children and the ARIA approach in adults and older people.

3) A combined approach to asthma and COPD has been proposed for older people, as the two diseases overlap and are often difficult to differentiate, particularly at the primary care level. Moreover, non-respiratory comorbidities will be included since older patients often have several diseases with poly-pharmacy.

4) To combine strategies for prevention and control.

- 5) To place a special emphasis on older and/or underserved patients.
- 6) To implement cost-effective policies for the prevention of chronic respiratory diseases.

7) To promote active and healthy ageing. AIRWAYS-ICPs places a particular interest in cultural and societal aspects of the diseases in a project centred on the patient.

8) Interactions will take place between several sections of AIRWAYS-ICPs in order to develop ICPs (fig. 3). Health technology assessment will lead to recommendations that will be evaluated in each country (or EU region) in order to develop multi-sectoral ICPs which may differ depending on the differences within the health systems, and on the socioeconomic and political priorities of the different countries.

8) Redesign care pathways using simulator tools (in older people)

Health costs associated with the long-term care of older people have increased in all countries. Computerbased simulation tools may provide integrated care services to older people. The simulation is used for decision-making in healthcare systems by increasing efficiency and reducing unnecessary cost, while maintaining or improving quality of care [57]. It is linked to the processes of change or reform of the system [58], and is used as a tool to address the complexity of healthcare systems (healthcare ecosystem) in which all stakeholders interact (patients, managers, policy makers and professionals). Examples are applied to infectious diseases [59]. The simulation allows the identification of treatment effects in longitudinal healthcare data [60], preventing technology-induced errors in healthcare [61]. In the area of "AIRWAYS ICPs", computational analysis has been used to analyse the role of asthma in airway mechanics parameters [62].

LTCMAS (Long-Term Care Multi-Agent Systems) [63] is a simulator that, as a starting point, used a holistic model of care systems for people that need long-term care, the Sustainable Socio-Health Model (SSHM). The implementation of the simulator on the Jason multi-agent platform allows the tool to include human interactions, preferences and social abilities that take place between older people and the staff of healthcare systems (health and social workers). The use of this multi-agent platform provides the required scalability for simulating population sizes of different orders of magnitude. The closed-loop design of the proposed simulator permits repeated simulation of successive interactions of the target population with the healthcare system. The simulator may forecast the long-term effects of different policies on the considered population as well as on the healthcare system.

Using the Spanish simulation tool LTCMAS [63] as a prototype, a new version will be adapted to the AIRWAYS patient group (LCT+ AIRWAYS ICPs). LCT+ AIRWAYS ICPs will be available in primary care centres through health information systems to assist physicians in the stratification of patients and choice of pathways, including an attempt to include resource use/cost implications.

9) Tackling chronic respiratory diseases across the life cycle

Pre-natal and early-life events have a major impact on the development of chronic diseases in adults [64, 65] and older people, including diabetes [66], coronary heart diseases [67], asthma [68], COPD [3] or neurodegenerative diseases [69]. A better understanding of these links will make it possible to propose effective novel prevention strategies to promote active and healthy ageing.

The developmental origin of ageing is on the EU political agenda. The Polish Priority of the EU Council (2011) promoted the recognition, prevention and management of chronic respiratory diseases in children to ultimately affect healthy ageing [26]. The developmental determinants of non-communicable diseases in ageing were reinforced during the Cyprus Presidency of the EU Council (2012), which proposed to fight against non-communicable diseases across the life cycle [27]. A meeting at the European Parliament, organised by the Region Languedoc Roussillon and under the auspices of the Cyprus EU Priority (November 2012), was focussed on chronic respiratory diseases [28].

In order to find novel health promotion strategies in non-communicable diseases and to promote value creation, pre-natal and early life events were discussed in a meeting on December 2–3, 2013 by the Region Languedoc Roussillon and under the auspices of the frame of Action B3 of the EIP on AHA.

10) Multi-sectoral, multi-country initiative

Members of each European country will be involved in a multi-sectoral approach: primary and secondary care, healthcare professionals (including pharmacists and nurses), social carers, patients and policy makers. Patients' organisations and major European scientific societies are partners of the WHO Collaborating Centre for Asthma and Rhinitis for this initiative. EUREGHA will help to deploy AIRWAYS-ICPs in the EU regions. Partners outside the EU will also be involved in the initiative. Education and coaching for all stakeholders with patients' organisations will be developed.

Interactions with the private sector have already been established with, as an example, Eurobiomed (www. eurobiomed.org; Commitment for Action B3 Action Plan), the focal point for the economic growth of MACVIA-LR (Contre les Maladies Chroniques pour un Vieillissement Actif; Fighting Chronic Diseases for Active and Healthy Ageing).

Added value

AIRWAYS-ICPs is a demonstration project that follows the recommendations of the EU (Council Conclusions) [25, 26] and which may be the model for ICPs in other chronic diseases for Action Plan B3 of the EIP on AHA.

The project does not duplicate actions that can be taken at the country level, but rather highlights problems that are not sufficiently addressed, and facilitates or enables rectification of these needs. As an example, fewer than 10 EU countries have a national asthma plan under the auspices of the Ministry of Health. Moreover, in many European regions, although healthcare is delivered by regions, the existence of regional plans is scarce.

AIRWAYS-ICPs will be built using the solutions for chronic respiratory diseases that already exist in countries or regions, as well as with the expertise of health professionals across Europe and beyond. The solutions that have been validated by professionals or that have already evidenced their success will be promoted in order to reduce fragmentation.

This project responds to the 3053rd EU Council conclusions: "innovative approaches for chronic diseases in public health and healthcare systems" adopted on December 7, 2010 and to the United Nations High Level meeting (2011). Asthma and allergic diseases are common chronic respiratory diseases and 200 million subjects are affected in Europe. Furthermore, the project uses ICT – innovative simulation tools. It focuses on the conclusions of the 3131st session of the EU Council (2011) on the Prevention and Control of CRDs in Children. Asthma plans are particularly effective in underserved populations and attempts will be undertaken to reduce health inequities.

The project will help to achieve the objective of an active ageing, and responds to the 3206th Council Conclusions [27] that recommend the initiation of early diagnosis and treatment of chronic diseases as early as possible in order to improve active and healthy ageing.

The aim of AIRWAYS-ICPs is to improve healthy life years and to reduce burden (emergency visits, avoidable hospitalisations, disability and costs) while improving quality of life worldwide, and, in the longer term, to reduce disease incidence by new and innovative prevention strategies.

AIRWAYS-ICPs has a clear strategic relevance with regard to the EU Health Strategy as it will bring added value to the existing public health knowledge:

- To propose a common framework for chronic respiratory disease (and for comorbidities) ICPs for the entire EU which can then be expanded to other regions (*e.g.* the Commonwealth of Independent States) and which will allow comparability and trans-national initiatives.
- To help risk stratification in chronic respiratory disease patients, using a common strategy.
- To develop cost-effective policies, in particular strengthening those on smoking and environment exposure.
- To have a significant implication on the health of citizens in the short term (reduction of morbidity, improvement of education in children and of work in adults) and in the long term (healthy ageing).
- To propose a common simulation tool for the entire EU in order to assist physicians in the segmentation of patients and in the choice of pathways.

Acknowledgements

The members of the AIRWAYS-ICPs study group are as follows: J. Bousquet (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; UM1, University 1, Montpellier; and Fondation Partenariale, France), A. Addis (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action, Regione Emilia-Romagna, Italy), I. Adcock (National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK), I. Agache (ARIA, Allergic Rhinitis and Its Impact on Asthma; Romanian Alliance against Chronic Respiratory Diseases; Faculty of Medicine, Transylvania University, Brasov, Romania), A. Agusti (Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias, Spain), N. Aït-Khaled (The Union), R. Akdağ (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C.A. Akdis (SIAF, Swiss Institute of Allergy and Asthma Research and University of Zurich; and Christine Kühne - Center for Allergy Research and Education, Davos, Switzerland), M. Akdis (SIAF, Swiss Institute of Allergy and Asthma Research and University of Zurich, Switzerland), A. Alonso (Hospital Clínic/FCRB, Barcelona, Spain), P. Altan (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), T. Altunsu (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C. Andersen (APFQ, Associação Portuguesa de Fibrose Quística), A. Andrianarisoa (SPLF, Espace francophone de Pneumologie), I. Annesi-Maesano (ARIA, Allergic Rhinitis and Its Impact on Asthma), I.J. Ansotegui (ARIA, Allergic Rhinitis and Its Impact on Asthma), J.M. Anto (MeDALL, Mechanisms of the Development of Allergy; Centre for Research in Environmental Epidemiology (CREAL); IMIM (Hospital del Mar Medical Research Institute); Universitat Pompeu Fabra (UPF); and CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain), L. Araujo (Porto Age-Up consortium; APA, Associação Portuguesa de Asmáticos, Portugal), T. de Araujo (FPP, Fundação Portuguesa do Pulmão), A. Arias Cruz (Colegio Mexicano de Inmunología Clínica y Alergia; SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), N. Arpacı (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), A. Arrobas (PNDR,

Portuguese National Programme for Respiratory Diseases), B. Aytaç (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C. Bachert (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept Respiratory Medicine, Ghent University Hospital, Gent, Belgium), C.E. Baena-Cagnani (ARIA, Allergic Rhinitis and Its Impact on Asthma; Research Centre in Respiratory Medicine (CIMER), Faculty of Medicine, Catholic University, Cordoba, Argentina), C. Báez Loyola (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), C. Bai (Shanghai Respiratory Research Institute, Respiratory Society, Chinese Medical Association, China; Chinese Alliance against Lung Cancer), A. Baigenzhin (EuroAsian Respiratory Society, Astana City, Kazakhstan), C. Barbara (PNDR, Portuguese National Programme for Respiratory Diseases), P.J. Barnes (National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK), R.H. Bárnica Alvarado (Colegio Mexicano de Inmunología Clínica y Alergia), E.D. Bateman (ARIA, Allergic Rhinitis and Its Impact on Asthma; Division of Pulmonology, Department of Medicine, Faculty of Health Sciences, University of Cape Town, South Africa), H. Batura-Gabreel (Polish Alliance against Chronic Respiratory Diseases), L. Beck (Health Innovation Centre of Southern Denmark, Region of Southern Denmark), A. Bedbrook (University Hospital Montpellier; and MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), B. Beghé (ARIA, Allergic Rhinitis and Its Impact on Asthma), M. Beji (SPLF, Espace francophone de Pneumologie), E.H. Bel (Academic Medical Centre, University of Amsterdam, the Netherlands), B. Bello Rivera (Colegio Mexicano de Inmunología Clínica y Alergia), A. Ben Kheder (SPLF, Espace francophone de Pneumologie), O. Benezet (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), K.S. Bennoor (ARIA, Allergic Rhinitis and Its Impact on Asthma; Bangladesh Lung Foundation and National Institute of Diseases of Chest and Hospital, Mohakhali, Dhaka, Bangladesh), M. Benson (Centre for Individualised Medicine, Dept of Clinical and Experimental Sciences, Linköping University, Linköping, Sweden), K.C. Bergman (GA²LEN, Global Allergy and Asthma European Network; Charité University Hospital, Allergy Centre Charité, Berlin, Germany), J. Beránková (SPCCH, ZO Association of Respiratory Ill Patients, Hradec Králové; CARO, Czech Alliance against Chronic Respiratory Diseases), M. Bernabeu-Wittel (EIPon-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Aura Andalucia, Spain; and Andalusian Healthcare Service), F. Berrissoul (SPLF, Espace francophone de Pneumologie), M. Bewick (NHS England, UK), A. Bialozewski (Polastma, Poland), C. Bindslev-Jensen (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, Denmark), H. Blain (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), M.S. Blaiss (ARIA, Allergic Rhinitis and Its Impact on Asthma), F. Blasi (ERS, European Respiratory Society; Dept of Pathophysiology and Transplantation, University of Milan, IRCCS Ca Granda, Milan, Italy), G. Bochenek (Polish Alliance against Chronic Respiratory Diseases), A. Bodzenta-Łukaszyk (Polish Alliance against Chronic Respiratory Diseases), M. Bogic (Faculty of Medicine, University of Belgrade; Association for Asthma and COPD in Serbia; and Clinic for Allergology and Immunology, Clinical Centre of Serbia, Serbia), M. Bonini (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Public Health and Infectious Diseases, "Sapienza" University of Rome, Rome, Italy), S. Bonini (ARIA, Allergic Rhinitis and Its Impact on Asthma; Second University of Naples and Institute of Translational Medicine, Italian National Research Council), P. Boros (Polish Alliance against Chronic Respiratory Diseases), J. Bortkiewicz (Polish Alliance against Chronic Respiratory Diseases), L.P. Boulet (ARIA, Allergic Rhinitis and Its Impact on Asthma; Institut universitaire de cardiologie et de pneumologie de Québec, Université Laval, Québec City, QC, Canada), A. Bourdin (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; UM1, University 1, Montpellier; and INSERM, U1046, France), R. Bourret (University Hospital Montpellier; and MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), P.J. Bousquet (ARIA, Allergic Rhinitis and Its Impact on Asthma), A. Breborowicz (Polish Alliance against Chronic Respiratory Diseases), A. Briggs (Health Economics and Health Technology Assessment, Institute of Health and Wellbeing, University of Glasgow, Glasgow, UK), C.E. Brightling (National Institute for Health Research, Leicester Respiratory Biomedical Research Unit, Glenfield Hospital, Leicester, UK), J. Brozek (ARIA, Allergic Rhinitis and Its Impact on Asthma; Depts of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, ON, Canada), Z. Brzoza (Polish Alliance against Chronic Respiratory Diseases), R. Buhl (Pulmonary Department, III, Medical Centre, Mainz University Hospital, Mainz, Germany), C. Bunu (Romanian Alliance against chronic respiratory diseases), P.J. Burney (National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK), A. Bush (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Paediatric Respiratory Medicine, Royal Brompton Hospital and National Heart and Lung Institute, Imperial College, London, UK), S. Býma (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Society of General Medicine), F. Caballero-Fonseca (Centro Medico Docente La Trinidad, Catacas, Venezuela), D. Caimmi (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France; ARIA, Allergic Rhinitis and Its Impact on Asthma), B. Cakır (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), M.A. Calderon (ARIA, Allergic Rhinitis and Its Impact on Asthma; University of Costa Rica, San Jose, Costa Rica; and Section of Allergy and Clinical Immunology, Imperial College London, Royal Brompton Hospital, London, UK), P. Calverley (Institute of Ageing and Chronic Disease, University of Liverpool and University Hospital Aintree, Liverpool, UK), M.A. Calvo (Pediatrics Dept, Medicine Faculty, Austral University, Chile), P.A. Camargos (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Pediatrics, Medical School, Federal University of Minas Gerais, Brazil), I. Cameron (Director of Public Health for Leeds, UK), T. Camuzat (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), G.W. Canonica (ARIA, Allergic Rhinitis and Its Impact on Asthma; Allergy and Respiratory Diseases, IRCCS San Martino -IST - University of Genoa, Dept of Internal Medicine, Genoa, Italy), L.R. Caraballo (ARIA, Allergic Rhinitis and Its Impact on Asthma), R. Cardona (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), K.H. Carlsen (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; NAH, National Allergy Health Programme, Norway; and University of Oslo and Oslo University Hospital, Dept of Paediatrics, Oslo, Norway), W. Carr (ARIA, Allergic Rhinitis and Its Impact on Asthma), T.B. Casale (ARIA, Allergic Rhinitis and Its Impact on Asthma; American Academy of Allergy Asthma and Immunology and Creighton University and University of South Florida, FL, USA), M. Cazzola (University of Rome "Tor Vergata" Department of System Medicine, Rome, Italy), A.M. Cepeda Sarabia (ARIA, Allergic Rhinitis and Its Impact on Asthma; SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia; Allergy and Immunology Laboratory, Metropolitan University; and Simon Bolivar University, Barranquilla, Colombia), A. Cesario (IRCCS San Raffaele Pisana, Rome, Italy), N.H. Chavannes (ARIA, Allergic Rhinitis and Its Impact on Asthma; IPCRG, International Primary Care Respiratory Group; Dept of Public Health and Primary Care, Leiden University Medical Center, Leiden, the Netherlands), Y.Z. Chen (National Cooperative Group of Paediatric Research on Asthma, Asthma Clinic

and Education Center of the Capital Institute of Pediatrics, Peking and Center for Asthma Research and Education, Beijing, PR China), R. Chiron (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France; ARIA, Allergic Rhinitis and Its Impact on Asthma), E. Chkhartishvili (Chachava Clinic, David Tvildiani Medical University-AIETI Medical School, Gr. Robakidze University, Georgia), A. Chuchalin (ARIA, Allergic Rhinitis and Its Impact on Asthma; GARD, Global Alliance against chronic Respiratory Diseases (WHO); Pulmonology Research Institute and Russian Respiratory Society, Moscow, Russia), K.F. Chung (National Heart and Lung Institute, Imperial College London and Royal Brompton and Harefield NIHR Biomedical Research Unit, London, UK), S.C. Coban (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), J. Correia de Sousa (APMGF, Associação Portuguesa de Medicina Geral e Familiar (APMGF)/Núcleo de Doenças Respiratórias - GRESP), D.J. Costa (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), L. Cox (ARIA, Allergic Rhinitis and Its Impact on Asthma; Nova Southeastern University Osteopathic College of Medicine, Davie, FL, USA), G. Crooks (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; NHS Scotland, Glasgow, UK), M.G. Crooks (Centre for Cardiovascular and Metabolic Research, Hull York Medical School, UK), A.A. Cruz (ARIA, Allergic Rhinitis and Its Impact on Asthma; GARD, Global Alliance against chronic Respiratory Diseases (WHO); ProAR, Nucleo de Excelencia em Asma, Federal University of Bahia and CNPq, Salvador, Brazil), A. Custovic (ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; University of Manchester, Manchester, UK), E. Czarnobilska (Polish Alliance against Chronic Respiratory Diseases), U. Czechowska (Polish Alliance against Chronic Respiratory Diseases), R. Dahl (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis, Odense University Hospital, Denmark), P. Dąbrowiecki (Polish Alliance against Chronic Respiratory Diseases), S.E. Dahlen (CfA, The Centre for Allergy Research, The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden), M. David (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), F. De Blay (ARIA, Allergic Rhinitis and Its Impact on Asthma; SFA, Société française d'Allergologie; Strasbourg University, France), T. Dedeu (EUREGHA, European Regions and Health Authorities, Brussels, Belgium), D. Deleanu (ARIA, Allergic Rhinitis and Its Impact on Asthma; Romanian Alliance against chronic respiratory diseases; University of Medicine and Pharmacy Iuliu Hatieganu, Cluj-Napoca, Romania), P. Demoly (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; and UM1, University 1, Montpellier, France), P. Devillier (ARIA, Allergic Rhinitis and Its Impact on Asthma; UPRES EA 220, Université Versailles Saint Quentin, Hôpital Foch, Suresnes, France), T. Didi (SPLF, Espace francophone de Pneumologie), A. Didier (SPLF, Société de Pneumologie de Langue Française; Dept of Respiratory Medicine, University of Toulouse, France), S. Dimić-Janjić (Association for Asthma and COPD in Serbia; Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Serbia), A.T. Dinh Xuan (Service de Physiologie, Paris Descartes University EA 2511, Hôpital Cochin, Assistance Publique Hôpitaux de Paris, France), R. Djukanovic (University Southampton Faculty of Medicine and NIHR Southampton Respiratory Biomedical Research Unit, UK), A. Doboszyńska (Polish Alliance against Chronic Respiratory Diseases), D. Dokic (ARIA, Allergic Rhinitis and Its Impact on Asthma; University Clinic of Pulmology and Allergy, University "Ss. Cyril and Methodius", Skopje, Macedonia), H. Douagui (ARIA, Allergic Rhinitis and Its Impact on Asthma; Service de pneumo-allergologie, Centre Hospitalo-Universitaire de Béni-Messous, Algiers, Algeria), R. Dubakiene (ARIA, Allergic Rhinitis and Its Impact on Asthma; LSACI, Lithuanian Society of Allergology University Faculty of Medicine, Lithuania; Vilnius University Faculty of Medicine, Lithuania), A. Dudvarski-Ilic (Faculty of Medicine, University of Belgrade, Serbia; Association for Asthma and COPD in Serbia; and Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Serbia), A. Dymek (Polish Alliance against Chronic Respiratory Diseases), S. Eglin (NHS R&D North West, Faculty of Health and Life Sciences, University of Liverpool, UK), A. El-Meziane (SPLF, Espace francophone de Pneumologie), F. Elliot (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; NHS Scotland, Edinburgh, UK), R. Emuzyte (ARIA, Allergic Rhinitis and Its Impact on Asthma; LSACI, Lithuanian Society of Allergology University Faculty of Medicine, Lithuania; Vilnius University Faculty of Medicine, Lithuania), P. Ergün (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), L. Fabbri (Regione Emilia-Romagna, Italy; Dept of Oncology, Haematology and Respiratory Diseases, Policlinic of Modena, University of Modena and Reggio Emilia, Modena, Italy), A.M. Fal (Polish Alliance against Chronic Respiratory Diseases), A. Fink Wagner (GAAPP, Global Allergy and Asthma Patient Platform, Vienna, Austria), M. Fletcher (GARD, Global Alliance against chronic Respiratory Diseases (WHO); Education for Health, Warwick, UK), W.J. Fokkens (ARIA, Allergic Rhinitis and Its Impact on Asthma; Academic Medical Centre, University of Amsterdam, the Netherlands; European Rhinology Society), J. Fonseca (ARIA, Allergic Rhinitis and Its Impact on Asthma; Porto Age-Up consortium, Portugal; PNDR, Portuguese National Programme for Respiratory Diseases; Dept of Health Information and Decision Sciences and CINTESIS, Porto University Medical School; Allergy, Hospital S. Joao and Instituto and Hospital CUF Porto, Portugal), A. Franco (Internal and Geriatric Medicine, University of Nice -Sophia Antipolis, France), P. Frith (Repatriation General Hospital, Adelaide, Australia), A. Furber (Director of Public Health, Wakefield Council, UK), M. Gaga (7th Resp. Med. Dept and Asthma Centre; and Athens Chest Hospital, Athens, Greece), A. Gamkrelidze (ARIA, Allergic Rhinitis and Its Impact on Asthma; National Center for Disease Control and Public Health of Georgia), J. Garcés (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; Polibienestar Research Institute, University of Valencia, Spain), J. Garcia-Aymerich (MeDALL, Mechanisms of the Development of Allergy; Centre for Research in Environmental Epidemiology (CREAL); IMIM (Hospital del Mar Medical Research Institute); Universitat Pompeu Fabra (UPF); CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain), G. Gaszczyk (Polish Alliance against Chronic Respiratory Diseases), J.E. Gereda (Allergy and Immunology Division, Clinica Ricardo Palma, Lima, Peru), R. Gerth van Wijk (ARIA, Allergic Rhinitis and Its Impact on Asthma; Section of Allergology, Dept of Internal Medicine, Erasmus Medical Centre, Rotterdam, the Netherlands), E. Göktaş (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), C. Gomes (ANTDR, Associação Nacional da Tuberculose e Doenças Respiratórias, Portugal), J. Gomez Vera (Colegio Mexicano de Inmunología Clínica y Alergia), M. Gonsalves (Porto Age-Up consortium, Portugal), R.A. González Galván (COMPENDIA, Mexico), M. Gotua (Center of Allergy and Immunology, Georgian Association of Allergology and Clinical Immunology, Tbilisi, Georgia), L. Grouse (University of Washington School of Medicine, Faculty of the Department of Neurology, USA), K. Gryga (Polish Alliance against Chronic Respiratory Diseases), J. Guggiari (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), A. Gündoğan (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), M.A. Guzmán (ARIA, Allergic Rhinitis and Its Impact on Asthma; Immunology and Allergology Division, Dept of Medicine, Clinical Hospital University of Chile, Chile), T. Haahtela (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept

of Allergy, Skin and Allergy Hospital, Helsinki University Hospital, Finland), D. Harrison (Director of Public Health for Blackburn with Darwen, UK), M. Hayot (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), L.G. Heaney (Centre for Infection and Immunity, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, UK), J. Heinrich (MeDALL, Mechanisms of the Development of Allergy), P.W. Hellings (ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; Dept of Otorhinolaryngology, Head and Neck Surgery, University Hospitals Leuven, Belgium), B. Hellquist-Dahl (ARIA, Allergic Rhinitis and Its Impact on Asthma), D. Henderson (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; NHS Scotland, Glasgow, UK), J. Hooper (Director of Public Health for Kirklees, UK), J.O'B. Hourihane (ARIA, Allergic Rhinitis and Its Impact on Asthma), M. Humbert (SPLF, Société de Pneumologie de Langue Française), J. Hyánek (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Association of Help to Chronically Ill Children), M. Hyland (School of Psychology, University of Plymouth, UK), G. Iaccarino (Regione-Campania, Italy, EIP on AHA Reference Site; Dept of Medicine and Surgery, University of Salerno; and IRCCS Multimedica, Milano, Italy), Iduñate Palacios (COMPENDIA, Mexico), J.C. Ivancevich (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), D. Jakovenko (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), M. Jansová (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Cystic Fibrosis Association), J.R. Jardim (Respiratory Diseases, Escola Paulista de Medicina of Federal University of Sao Paulo, Brazil), E. Jassem (Polish Alliance against Chronic Respiratory Diseases), E. Jaworska (Polish Alliance against Chronic Respiratory Diseases), R. Jaller Raad (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), C. Jeandel (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), C. Jenkins (The George Institute for Global Health and The University of Sydney, Australia), J. Jerzynska (Polish Alliance against Chronic Respiratory Diseases), S.L. Johnston (ARIA, Allergic Rhinitis and Its Impact on Asthma; Airway Disease Infection Section, National Heart and Lung Institute, Imperial College London, UK), O. Jonquet (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), G. Joos (Dept Respiratory Medicine, Ghent University Hospital, Gent, Belgium), K.S. Jung (Hallym University College of Medicine; Hallym University Sacred Heart Hospital, South Korea), D. Jurásková (CARO, Czech Alliance against Chronic Respiratory Diseases; Pneumological Section of Nurses in ČAS), J. Just (Allergology Dept, Trousseau Hospital, APHP, UPMC, Paris, France), M. Kackzorek (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; Eurobiomed), T. Kakillioğlu (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), O. Kalayci (ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; Global Alliance against Chronic Respiratory Diseases (GARD); Hacettepe University School of Medicine, Paediatric Allergy and Asthma Unit, Hacettepe, Ankara, Turkey), G.B. Karakoç (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), D. Kardas-Sobantka (Polish Alliance against Chronic Respiratory Diseases), C. Karlıkaya (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), S. Karunanithi (Director of Public Health, Lancashire County Council, UK), T. Keil (MeDALL, Mechanisms of the Development of Allergy; Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin; and Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany), B. Keskinkılıç (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), N. Khaltaev (ARIA, Allergic Rhinitis and Its Impact on Asthma; GARD, Global Alliance against chronic Respiratory Diseases (WHO)), G. Khayat (SPLF, Espace francophone de Pneumologie), Y.Y. Kim (ARIA, Allergic Rhinitis and Its Impact on Asthma), A. Kocabas (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), B. Koffi N'goran (SPLF, Espace francophone de Pneumologie), N. Köktürk (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), V. Kolek (CARO, Czech Alliance against Chronic Respiratory Diseases), R. Komar (Polish Alliance against Chronic Respiratory Diseases), G.H. Koppelman (University of Groningen, University Medical Center Groningen, Dept of Paediatric Pulmonology and Paediatric Allergology, Beatrix Children's Hospital, Groningen, the Netherlands), S. Kos (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech, Civic Association Against COPD (ČOPN)), M. Kosdak (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), G. Kostic (Faculty of Medicine, University of Kragujevac; and Paediatric Clinic, Clinical Centre Kragujevac, Serbia), M.L. Kowalski (Dept Immunology, Rheumatology and Allergy, Faculty of Medicine, Medical University of Lodz, Poland), J. Kozub (Polish Alliance against Chronic Respiratory Diseases), E. Králíková (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Working group for Prevention and Treatment of Tobacco Addiction), M. Krawiec (Polish Alliance against Chronic Respiratory Diseases), A. Kucharczyk (Polish Alliance against Chronic Respiratory Diseases), I. Kull (MeDALL, Mechanisms of the Development of Allergy; Karolinska Institutet, Dept of Clinical Science and Education, Institute of Environmental Medicine, Stockholm, Sweden), P. Kuna (ARIA, Allergic Rhinitis and Its Impact on Asthma; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; Polastma, Poland; GARD, Global Alliance against chronic Respiratory Diseases (WHO); Dept of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Poland), I. Kupryś-Lipińska (Polish Alliance against Chronic Respiratory Diseases), V. Kvedariene (ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; LSACI, Lithuanian Society of Allergology University Faculty of Medicine, Lithuania; Lithuanian-asthma-patients-clubs-association, Lithuania; Pulmonology and Allergology Center, Vilnius University, Lithuania), A. Kwśniewsk (Polish Alliance against Chronic Respiratory Diseases), J.E. de La Coussaye (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), D. Larenas-Linnemann (ARIA, Allergic Rhinitis and Its Impact on Asthma), Z. Lazić (Faculty of Medicine, University of Kragujevac; and Clinic for Pulmonary Disease, Clinical Centre Kragujevac, Serbia), L.T. Le (ARIA, Allergic Rhinitis and Its Impact on Asthma; GARD, Global Alliance against chronic Respiratory Diseases (WHO); University of Medicine and Pharmacy, Hochiminh City, Vietnam), J. Li (ARIA, Allergic Rhinitis and Its Impact on Asthma), P. Lieberman (ARIA, Allergic Rhinitis and Its Impact on Asthma), B. Lipworth (ARIA, Allergic Rhinitis and Its Impact on Asthma), K.C. Lodrup Carlsen (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; NAH, National Allergy Health Programme, Norway; University of Oslo and Oslo University Hospital, Dept of Paediatrics, Oslo, Norway), A.L. López González (COMPENDIA, Mexico), D.N. López Lizarraga (Colegio Mexicano de Inmunología

Clínica y Alergia), R. Louis (CHU Liege, GIGA I³ Research Center, University of Liege, Belgium), J.S. Lozano Sáenz (COMPENDIA, Mexico), H. Łuczak-Aszkowska (Polish Alliance against Chronic Respiratory Diseases), V. Lund (European Rhinology Society), A. Macías Weinmann (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), W. MacNee (Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK), T. Maglakelidze (Medical Diagnostic Centre of the Tbilisi State University, Georgia), B. Mahboub (ARIA, Allergic Rhinitis and Its Impact on Asthma), A. Mair (Directorate of Finance, eHealth and Pharmaceuticals, Scottish Government Health Department, Edinburgh, UK), I. Majer (University of Batislava, Slovakia), M.J. Makela (Dept of Dermatology, Skin and Allergy Hospital, Helsinki University Hospital, Finland), P. Manning (Dept of Medicine, Royal College of Surgeons in Ireland (Medical School) Bon Secours Hospital, Dublin, Ireland), M. de Manuel Keenoy (Kronikgune, Basque Region, Spain), G.D. Marshall (ARIA, Allergic Rhinitis and Its Impact on Asthma), F. Martin (SPLF, Espace francophone de Pneumologie), E.A. Martínez Infante (Colegio Mexicano de Inmunología Clínica y Alergia), M.R. Masjedi (ARIA, Allergic Rhinitis and Its Impact on Asthma; GARD, Global Alliance against chronic Respiratory Diseases (WHO); Chronic Respiratory Diseases Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Science, Tehran, Iran), M. Maurer (GA²LEN, Global Allergy and Asthma European Network; Charité University Hospital, Allergy Centre Charité, Berlin, Germany), A. Mazon (Unit of Paediatric Allergy and Pneumology, Children's Hospital, Instituto de Investigacion Sanitaria La Fe, Valencia, Spain), M. Medina Avalos (Colegio Mexicano de Inmunología Clínica y Alergia), E. Melén (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; Karolinska Institutet, Dept of Clinical Science and Education, Institute of Environmental Medicine, Stockholm, Sweden), E. Melo-Gomes (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; PNDR, Portuguese National Programme for Respiratory Diseases), A. Menzies-Gow (Royal Brompton Hospital, London, UK), G. Mercier (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), J. Mercier (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; and UM1, University 1, Montpellier, France), J.P. Michel (Geneva Medical School and University Hospitals, Switzerland), N. Miculinic (University Hospital for Pulmonary Diseases Jordanovac, Zagreb, Croatia), J. Mierzejewska (Polish Alliance against Chronic Respiratory Diseases), W. Mierzwa (Polish Alliance against Chronic Respiratory Diseases), F. Mihaltan (ARIA, Allergic Rhinitis and Its Impact on Asthma; Romanian Alliance against chronic respiratory diseases; Institute of Pneumology Marius Nasta, Bucharest, Romania), M. Mikulášková (CARO, Czech Alliance against Chronic Respiratory Diseases; SPCCH ZO Club of Asthmatics, Olomouc, Czech Republic), B. Milenkovic (Faculty of Medicine, University of Belgrade, Serbia; Association for Asthma and COPD in Serbia; Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Serbia), P. Minić (Faculty of Medicine, University of Belgrade; and Institute for Mother and Child, Belgrade, Serbia), Y. Mohammad (Tishreen University School of Medicine, Dept of Internal Medicine, WHO - EMRO collaborating center for training and research in Chronic Respiratory Diseases, Lattakia, Syria), M. Molimard (Bordeaux University, France), I. Momas (Paris Descartes University, Dept of Public health and biostatistics, EA 4064 and Paris municipal Department of social action, childhood, and health, Paris, France), I. Monsoní (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; Polibienestar Research Institute, University of Valencia, Spain), A. Montilla-Santana (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site, Aura Andalucia, Spain), M. Morais-Almeida (Immunoallergy Dept, Hospital CUF-Descobertas, Lisbon, Portugal; SPAIC, Sociedade Portuguesa de Alergologia e Imunologia Clínica, Portugal), B. Morfin Maciel (COMPENDIA, Mexico), M. Morgan (Respiratory National Clinical Director, NHS England, UK), J. Mullol (Rhinology Unit and Smell Clinic, ENT Dept, Hospital Clínic, IDIBAPS; CIBERES, Barcelona, Spain), D. Mungan (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), M. N'Diaye (Service de Médecine Interne et Pathologies Professionnelles, Hôpital Polyclinique de Dakar (IHS), Sénégal), M. Nakládalová (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Society of Occupational Diseases), R. Naclerio (ARIA, Allergic Rhinitis and Its Impact on Asthma), S. Nafti (ARIA, Allergic Rhinitis and Its Impact on Asthma; Mustapha Hospital, Algiers, Algeria), L. Namazova-Baranova (ARIA, Allergic Rhinitis and Its Impact on Asthma), K. Nekam (ARIA, Allergic Rhinitis and Its Impact on Asthma; Hospital of the Hospitaller Brothers in Buda, Budapest, Hungary), A. Neou (GA²LEN, Global Allergy and Asthma European Network; Charité University Hospital, Allergy Centre Charité, Berlin, Germany), B. Nestorović (Faculty of Medicine, University of Belgrade; and University Children's Hospital, Belgrade, Serbia), L. Nicod (Service de Pneumologie, 1011 CHUV-Lausanne, Switzerland), E. Nizankowska-Mogilnicka (Dept of Pulmonology, Jagiellonian University School of Medicine, Krakow, Poland), T.D. Nyembue (Kinshasa University, ENT Dept, Democratic Republic of Congo), B. Ochojska (Polish Alliance against Chronic Respiratory Diseases), A. Obojski (Polish Alliance against Chronic Respiratory Diseases), R. O'Hehir (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Monash University, Melbourne, Australia), K. Ohta (ARIA, Allergic Rhinitis and Its Impact on Asthma; National Hospital Organization, Tokyo National Hospital and Teikyo University School of Medicine, Tokyo, Japan), Y. Okamoto (Dept of Otorhinolaryngology, Chiba University Hospital, Chiba, Japan), K. Okubo (Dept of Otolaryngology, Nippon Medical School, Tokyo, Japan), J. Olivas Villagrán (COMPENDIA, Mexico), S. Orea Hernández (Colegio Mexicano de Inmunología Clínica y Alergia), M.P. Orru (Pharmacist, Italy), A. Østrem (IPCRG, International Primary Care Respiratory Group), S. Ouedraogo (Centre Hospitalier Universitaire Pédiatrique Charles de Gaulle, Ouagadougou, Burkina Faso), R. Ozacar (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), P. Paggiaro (Cardio-Thoracic and Vascular Dept, University Hospital of Pisa, Italy), S. Palkonen (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; EFA, European Federation of Allergy and Airways Diseases patient's association), S. Palmer (Centre for Reviews and Dissemination (CRD), University of York, York, UK), P. Panzner (Dept of Immunology and Allergology, Faculty of Medicine in Plzen, Charles University Prague, Czech Republic), N.G. Papadopoulos (ARIA, Allergic Rhinitis and Its Impact on Asthma; EAACI, European Academy of Allergy and Clinical Immunology; University of Manchester, Manchester, UK; Allergy Dept, 2nd Paediatric Clinic, University of Athens, Greece), A. Papi (Regione Emilia-Romagna; Ferrara University, Italy), G. Passalacqua (ARIA, Allergic Rhinitis and Its Impact on Asthma; Allergy and Respiratory Diseases, IRCCS San Martino - IST - University of Genoa, Dept of Internal Medicine, Genoa, Italy), I. Pavord (NDM Research Building, University of Oxford, UK), R. Pawankar (Nippon Medical School, Bunkyo-ku, Tokyo, Japan), S. Petrović (Faculty of Medicine, University of Novi Sad; Institute for child and adolescents health care of Vojvodina; and Serbian Childhood Asthma Network, Serbia), V. Petru (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Society of Allergology and Clinical Immunology), B. Pigearias (SPLF, Espace francophone de Pneumologie), D. Plavec (Children's Hospital Srebrnjak, Zagreb, School of Medicine, University

J.J. Strossmayer, Osijek, Croatia), W. Pohl (Krankenhaus Hietzing, Dept of Pulmonary Diseases, KLI for experimental and clinical pneumology, Vienna, Austria), P. Pohunek (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Working Group of Paediatric Pneumology; Czech Initiative for Asthma (ČIPA)), T.A. Popov (Clinic of Allergy and Asthma, Medical University, Sofia, Bulgaria), D.S. Postma (MeDALL, Mechanisms of the Development of Allergy; University of Groningen, Dept of Pulmonology, GRIAC Research Institute University Medical Center Groningen, Groningen, the Netherlands), D. Price (ARIA, Allergic Rhinitis and Its Impact on Asthma; IPCRG, International Primary Care Respiratory Group; Academic Primary Care, University of Aberdeen, Aberdeen, UK), P. Pruzinec (University of Batislava, Slovakia), M. Pudelko (Polish Alliance against Chronic Respiratory Diseases), J.L. Pujol (University Hospital Montpellier; and MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), X. Quantin (University Hospital Montpellier; and MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France), A.M. Quintas (APA, Associação Portuguesa de Asmáticos, Portugal), K.F. Rabe (Christian Albrechts University Kiel; LungenClinic Grosshansdorf; Airway Research Center North (ARCN); and German Center for Lung Research (DZL), Germany), S. Radic (Hospital for children with pulmonary diseases, Belgrade; and Serbian Childhood Asthma Network, Serbia), F. Radier-Pontal (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France; ARIA, Allergic Rhinitis and Its Impact on Asthma; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site), E-K. Radziszewska (IPCRG, International Primary Care Respiratory Group), A. Rajpura (Director of Public Health for Blackpool, UK), J. Ratomaharo (SPLF, Espace francophone de Pneumologie), J. Redon (EIPon-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; Research Institute INCLIVA, University of Valencia; and CIBERObn, Health Institute Carlos III, Madrid, Spain), S. Reitamo (Dept of Dermatology, Skin and Allergy Hospital, Helsinki University Hospital, Finland), S. Rennard (University of Nebraska Medical Center, Division of Pulmonary, Critical Care, Sleep and Allergy, Nebraska Medical Center, Omaha, NE, USA), L. Ribeiro (SPAP, Sociedade Portuguesa de Alergologia Pediátrica), D. Říčný (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Association of Allergic and Asthmatic Children). C. Robalo-Cordeiro (Centre of Pneumology, Coimbra University Medical School, Coimbra, Portugal), C.G. Roberts (EAACI, European Academy of Allergy and Clinical Immunology), J. Roberts (Salford Royal NHS Foundation Trust, UK), J.M. Robine (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, INSERM, U710 and 988, France), J. Roca (Institut Clínic del Tòrax, Hospital Clinic, IDIBAPS, CIBERES, University of Barcelona, Spain), N. Roche (Pneumologie, AP-HP, Hôpital Cochin - Site Val de Grâce, Université Paris Descartes and SPLF, Société de Pneumologie de Langue Française, Paris, France), F. Rodenas (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, Reference Site; Polibienestar Research Institute, University of Valencia, Spain), B. Rogala (Dept and Clinic of Internal Diseases, Allergology and Clinical Immunology Medical University of Silesia, Katowice, Poland), A. Roggeri (Arcispedale S. Maria Nuova Hospital, Reggio Emilia, Regione Emilia-Romagna, Italy), C. Rolland (Association Asthme & Allergies, Boulogne-Billancourt, France), M. Roman (IPCRG, International Primary Care Respiratory Group), J. Rosado-Pinto (ARIA, Allergic Rhinitis and Its Impact on Asthma; EIPon-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; PNDR, Portuguese National Programme for Respiratory Diseases; GARD, Global Alliance against chronic Respiratory Diseases (WHO)), N. Rosario (Hospital de Clinicas, University of Parana, Brazil), M. Rottem (Division of Allergy Asthma and Clinical Immunology, Emek Medical Center, Afula, Israel), E. Royere (MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon, France; EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; Eurobiomed), D. Ryan (ARIA, Allergic Rhinitis and Its Impact on Asthma; IPCRG, International Primary Care Respiratory Group; Woodbrook Medical Centre, Loughborough; Allergy and Respiratory Research Group, Center for Population Health Sciences, The University of Edinburgh, Medical School, Edinburgh, UK), M. Rzeszutko-Grabowska (Polish Alliance against Chronic Respiratory Diseases), C. Sackesen (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), A. Sacre Hazouri (COMPENDIA, Mexico), H. Sagara (Dept of Respiratory Medicine, Dokkyo Medical University, Japan), B. Samolinski (EIP-on-AHA, European Innovation Partnership on Active and Healthy Ageing, B3 Commitment for Action; Polastma, Poland; Dept of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Poland), M. Sanchez-Borges (Dept of Allergy and Clinical Immunology, Centro Medico-Docente La Trinidad, Caracas, Venezuela), G.K. Scadding (The Royal National TNE Hospital, University College London, UK), P. Schmid-Grendelmeier (Allergy Unit, Dept of Dermatology, University Hospital, Zurich, Switzerland), H.J. Schünemann (Depts of Clinical Epidemiology and Biostatistics and Medicine, McMaster University, Hamilton, ON, Canada), V. Sedlák (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech National Centre for Severe Asthma (NCTA)), N.H. Segura Mendez (Dept of Allergy and Clinical Immunology, Centro Medico Nacional Siglo XXI, IMSS, Ciudad de México, Mexico), A. Shaik (NHS Scotland, Glasgow, UK), A. Sheikh (Allergy and Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Medical School, Edinburgh, UK; and Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital/Harvard Medical School, Boston, MA, USA), M. Shields (Child Health, Queen's University Belfast and Royal Belfast Hospital for Sick Children, UK), N. Siafakas (Dept of Thoracic Medicine, University Hospital of Heraklion, Heraklion, Greece), Y. Sibille (University Hospital of Mont-Godinne, Catholic University of Louvain, Yvoir, Belgium), P. Śliwiński (Polish Alliance against Chronic Respiratory Diseases), T. Similowski (Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", Paris; INSERM, UMR_S 1158 "Neurophysiologie Respiratoire Expérimentale et Clinique", Paris; AP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de Pneumologie et Réanimation Médicale (Département "R3S"), Paris; and Fonds de Dotation Recherche en Santé Respiratoire - Fondation du Souffle, France), F.E.R. Simons (ARIA, Allergic Rhinitis and Its Impact on Asthma), J.C. Sisul (Sociedad Paraguaya de Alergia Asma e Inmunología, Paraguay), A.C. Sisuz Alvariza (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), R. Skiepko (Polish Alliance against Chronic Respiratory Diseases), I. Small (National Advisory Group, Respiratory Managed Clinical Networks in Scotland), A.J. Soares (Porto Age-Up consortium, Portugal), M.L. Soares Branco (Associação-Respira, Portugal), O. Sola-Morales (HITT, Health Institute for Technology Transfer, Barcelona, Spain), D. Solé (Division of Allergy, Clinical Immunology and Rheumatology, Dept Pediatrics, Federal University of São Paulo, São Paulo, Brazil), H. Solorio Gomez (COMPENDIA, Mexico), T. Sooronbaev (ARIA, Allergic Rhinitis and Its Impact on Asthma; EuroAsian Respiratory Society; GARD, Global Alliance against chronic Respiratory Diseases (WHO); National Centre Cardiology and Internal Medicine, Bishkek, Kyrgyzstan), V. Spicak (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Society of Allergology and Clinical Immunology), O. Spranger (GAAPP, Global Allergy and Asthma Patient Platform, Vienna, Austria), I. Stanković (Association for Asthma and COPD in Serbia; Faculty of Medicine, University of Nis; and Clinic for Pulmonary Diseases, Clinical Center of Nis, Serbia), R. Stelmach (Pulmonary Division, InCor (Heart Institute), Hospital da Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Brazilí, A. Šteflová (CARO, Czech Alliance against Chronic Respiratory

Diseases; WHO Czech Country Office), P.J. Sterk (Academic Medical Centre, University of Amsterdam, the Netherlands), T. Stiris (Dept of Neonatal Intensive Care, Oslo University Hospital, Ulleval, Norway; Dept of Paediatrics, Nordland Hospital, Bodo, Norway; European Academy of Paediatrics (EAP-UEMS)), S.W. Stoloff (University of Nevada School of Medicine, Reno, NV, USA), P. Sud (Regional Medical Manager (North), NHS England, UK), J. Sunyer (MeDALL, Mechanisms of the Development of Allergy; Centre for Research in Environmental Epidemiology (CREAL); IMIM (Hospital del Mar Medical Research Institute); Universitat Pompeu Fabra (UPF); CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain), K. Targosz (Polish Alliance against Chronic Respiratory Diseases), V. Tellier (Observatoire wallon de la santé, Direction générale opérationnelle Pouvoirs locaux, action sociale et Santé, Service public de Wallonie, Belgium), M. Thomas (IPCRG, International Primary Care Respiratory Group), N.C. Thomson (NHS Scotland, Glasgow, UK), T. To (GARD, Global Alliance against chronic Respiratory Diseases (WHO)), P. Toche (SLaai, Sociedad Latinoamericana de Allergia, Asma e Immunologia), A. Todo-Bom (Immunoallergy Dept, Coimbra University Hospital, Coimbra, Portugal), V. Tomic-Spiric (Faculty of Medicine, University of Belgrade; and Clinic for Allergology and Immunology, Clinical Centre of Serbia, Serbia), E. Trebas-Pietraś (Polish Alliance against Chronic Respiratory Diseases), M. Triggiani (Dept of Medicine and Surgery, University of Salerno, Italy), M. Tucek (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Society of Occupational Medicine), B. Trzepióra (Polish Alliance against Chronic Respiratory Diseases), D. Tugay (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), R. Valenta (ARIA, Allergic Rhinitis and Its Impact on Asthma; Dept of Pathophysiology and Allergy Research, Centre of Pathophysiology, Infectology and Immunology, Medical University of Vienna, Austria), A.L. Valero (Thorax Institute, Hospital Clinic, IDIBAPS, University of Barcelona and CIBER Enfermedades Respiratorias, Spain), A. Valiulis (ARIA, Allergic Rhinitis and Its Impact on Asthma; Lithuanian National Alliance Against Chronic Respiratory Diseases (LACRD); LSACI, Lithuanian Society of Allergology University Faculty of Medicine, Lithuania; European Acacdemy of Paediatrics (EAP-UEMS); Vilnius University Faculty of Medicine, Lithuania), E. Valovirta (Dept of Lung Diseases and Clinical Allergology, Univ. of Turku, Finland), M. Van den Berge (Dept of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, the Netherlands), E. Van Ganse (Pharmacoepidemiology Unit and Respiratory Medicine, CHU-Lyon and UMR CNRS 5558, Claude-Bernard University Lyon, France), O. Vandenplas (ARIA, Allergic Rhinitis and Its Impact on Asthma; University Hospital of Mont-Godinne, Catholic University of Louvain, Yvoir, Belgium), T. Vasankari (FILHA, Finnish Lung Association), J. Vestbo (Dept of Respiratory Medicine J, Odense University Hospital, Denmark; Respiratory and Allergy research Group, Manchester Academic Health Science Centre, University of Manchester, UK), G. Vezzani (EIP on AHA B3 Action Group (Delivering Integrated Care Models), Regional Agency for Health and Social Care, Emilia-Romagna Region; and Arcispedale S.Maria Nuova/IRCCS, Research Hospital, Reggio Emilia, Italy), P. Vichyanond (Dept of Pediatrics, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand), G. Viegi (CNR, Institutes of Biomedicine and Molecular Immunology (IBIM), Palermo, and of Clinical Physiology (IFC), Pisa, Italy), C. Virchow (University Hospital, Rostock, Germany), L. Visier (University Hospital Montpellier; MACVIA-LR, Fighting Chronic Diseases for Healthy Ageing, Région Languedoc Roussillon; and UM1, University 1, Montpellier, France), C. Vogelmeier (Dept of Medicine, Pulmonary and Critical Care Medicine, University Medical Center Giessen and Marburg, Philipps-University Marburg, Germany; German Center for Lung Research (DZL)), T. Vontetsianos (Sotiria Hospital, Athens, Greece), J. Vorlicek (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Oncological Society), J. Vyskočilová (CARO, Czech Alliance against Chronic Respiratory Diseases; Czech Sleep Research and Sleep Medicine Society), R. Wagstaff (Acting Director of Public Health, Cumbria County Council, The Courts, Carlisle, UK), U. Wahn (Charité University Hospital, Allergy Centre Charité, Berlin, Germany), B. Wallaert (SFA, Société française d'Allergologie; Hôpital Albert Calmette, CHRU, Lille, France), D.Y. Wang (Yong Loo Lin School of Medicine, National University of Singapore, Singapore), I. Wegrzyn-Szkutnik (Polish Alliance against Chronic Respiratory Diseases), B. Whalley (School of Psychology, University of Plymouth, UK), M. Wickman (MeDALL, Mechanisms of the Development of Allergy; ARIA, Allergic Rhinitis and Its Impact on Asthma; Karolinska Institutet, Dept of Clinical Science and Education, Institute of Environmental Medicine, Stockholm, Sweden), E. Willak-Janc (Polish Alliance against Chronic Respiratory Diseases), D.M. Williams (Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC, USA), N. Wilson (Senior EU Health Specialist, North of England EU Health Partnership, UK), A. Windak (IPCRG, International Primary Care Respiratory Group), N. Yardım (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), B.P. Yawn (ARIA, Allergic Rhinitis and Its Impact on Asthma; Olmsted Medical Center, Dept of Research and University of Minnesota, Dept of Family and Community Health, Rochester, MN, USA), P.K. Yiallouros (ARIA, Allergic Rhinitis and Its Impact on Asthma; Cyprus International Institute for Environmental and Public Health in Association with Harvard School of Public Health; Cyprus University of Technology), F. Yıldız (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), A. Yorgancioglu (ARIA, Allergic Rhinitis and Its Impact on Asthma; Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), H. Yüksel (Global Alliance against Chronic Respiratory Diseases (GARD), Turkey), O.M. Yusuf (The Allergy and Asthma Institute, Pakistan; Planning Group, GARD), H.J. Zar (Dept of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, University of Cape Town, South Africa), N. Zhong (Guangzhou Institute of Respiratory Diseases and State Key Laboratory of Respiratory Diseases, Guangzhou Medical College, Guangzhou, China), M. Zidarn (ARIA, Allergic Rhinitis and Its Impact on Asthma; University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia), Z. Zietkowski (Polish Alliance against Chronic Respiratory Diseases), G. Zioło (Polish Alliance against Chronic Respiratory Diseases), S. Zivanovic (Faculty of Medicine, University of Nis; Serbian Childhood Asthma Network; and Paediatric Clinic, Clinical Centre of Nis, Serbia), Z. Żivković (Hospital for children with pulmonary diseases, Belgrade; and Serbian Childhood Asthma Network, Serbia), T. Zuberbier (GA²LEN, Global Allergy and Asthma European Network; Charité University Hospital, Allergy Centre Charité, Berlin, Germany), V. Zugic (Faculty of Medicine, University of Belgrade; and Clinic for Pulmonary Diseases, Clinical Centre of Serbia, Serbia), B. Zvezdin (Association for Asthma and COPD in Serbia; University of Novi Sad; and Institute for Pulmonary Diseases and TB, Clinical Centre Vojvodina, Serbia), and K. Zygmunt (Polish Alliance against Chronic Respiratory Diseases).

References

- Bousquet J, Khaltaev N. Global Surveillance, Prevention and Control of Chronic Respiratory Diseases. A Comprehensive Approach. Global Alliance against Chronic Respiratory Diseases. Geneva, World Health Organization Press, 2007.
- 2 Gibson GJ, Loddenkemper R, Sibille, et al., eds. European Lung White Book. 2nd Edn. Sheffield, European Respiratory Society, 2013.

- 3 Svanes C, Sunyer J, Plana E, *et al.* Early life origins of chronic obstructive pulmonary disease. *Thorax* 2010; 65: 14–20.
- 4 Perret JL, Dharmage SC, Matheson MC, *et al.* The interplay between the effects of lifetime asthma, smoking, and atopy on fixed airflow obstruction in middle age. *Am J Respir Crit Care Med* 2013; 187: 42–48.
- 5 Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Intern Med 2011; 155: 179–191.
- 6 Brozek JL, Bousquet J, Baena-Cagnani CE, *et al.* Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466–476.
- 7 Guyatt GH, Oxman AD, Vist GE, *et al.* GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ* 2008; 336: 924–926.
- Brozek JL, Akl EA, Compalati E, *et al.* Grading quality of evidence and strength of recommendations in clinical practice guidelines part 3 of 3. The GRADE approach to developing recommendations. *Allergy* 2011; 66: 588–595.
 Bateman ED, Hurd SS, Barnes PJ, *et al.* Global strategy for asthma management and prevention: GINA executive summary. *Eur Respir J* 2008; 31: 143–178.
- 10 Vestbo J, Hurd SS, Agusti AG, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Crit Care Med 2013; 187: 347–365.
- Gibson PG, Simpson JL. The overlap syndrome of asthma and COPD: what are its features and how important is it? *Thorax* 2009; 64: 728–735.
- 12 Pistelli R, Ferrara L, Misuraca C, *et al.* Practical management problems of stable chronic obstructive pulmonary disease in the elderly. *Curr Opin Pulm Med* 2011; 17: Suppl. 1, S43–S48.
- 13 Haahtela T, Tuomisto LE, Pietinalho A, *et al.* A 10 year asthma programme in Finland: major change for the better. *Thorax* 2006; 61: 663–670.
- 14 Kinnula VL, Vasankari T, Kontula E, et al. The 10-year COPD Programme in Finland: effects on quality of diagnosis, smoking, prevalence, hospital admissions and mortality. Prim Care Respir J 2011; 20: 178–183.
- 15 Souza-Machado C, Souza-Machado A, Franco R, et al. Rapid reduction in hospitalisations after an intervention to manage severe asthma. Eur Respir I 2010; 35: 515–521.
- 16 National Clinical Guideline Centre for Acute and Chronic Conditions. Chronic Obstructive Pulmonary Disease: Management of Chronic Obstructive Pulmonary Disease in Adults in Primary and Secondary Care (partial update). London, National Clinical Guideline Centre for Acute and Chronic Conditions, 2010. Available from: http:// guidance.nice.org.uk/CG101
- 17 Long Alliantie Nederland. Zorgstandaard astma Volwassenen [Standards of Care for Asthma in Adults]. Amersfoort, Long Alliantie Nederland, 2012. Available from: www.longalliantie.nl/files/6113/6752/1347/Zorgstandaard_Astma_ Volwassenen.pdf
- 18 Long Alliantie Nederland. Zorgstandaard astma Kinderen & Jongeren [Standards of Care for Asthma in Children and Young People]. Amersfoort, Long Alliantie Nederland, 2012. Available from: www.longalliantie.nl/files/6513/ 6752/1347/Zorgstandaard_Astma_Kinderen_en_Jongeren.pdf
- 19 Long Alliantie Nederland. Zorgstandaard COPD [Standards of Care for COPD]. Amersfoort, Long Alliantie Nederland, 2013. Available from: www.longalliantie.nl/files/5113/7994/2952/LAN_Zorgstandaard_COPD-2013juni.pdf
- 20 National Institute for Health and Clinical Excellence. Asthma. Quality standards. http://publications.nice.org.uk/ quality-standard-for-asthma-qs25 February 2013. Date last accessed: January 12, 2014.
- 21 QOF Clinical Indicators 2013/14: Summary Tables. www.eguidelines.co.uk/eguidelinesmain/external_guidelines/ qof.php April 2013. Date last accessed: January 12, 2014.
- 22 World Health Organization. Package of Essential NCD Interventions for Primary Health Care: Cancer, Diabetes, Heart Disease and Stroke, Chronic Respiratory Disease. Geneva, WHO Press, 2010.
- 23 Hamzaoui A, Ottmani S. Practical approach to lung health: lung health for everyone? *Eur Respir Rev* 2012; 21: 186–195.
- 24 English RG, Bateman ED, Zwarenstein MF, *et al.* Development of a South African integrated syndromic respiratory disease guideline for primary care. *Prim Care Respir J* 2008; 17: 156–163.
- 25 Samolinski B, Fronczak A, Włodarczyk A, et al. Council of the European Union conclusions on chronic respiratory diseases in children. Lancet 2012; 379: e45–e46.
- 26 Samolinski B, Fronczak A, Kuna P, *et al.* Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. *Allergy* 2012; 67: 726–731.
- 27 Council Conclusions on Healthy Ageing Across the Lifecycle. 3206th Employment, Social Policy, Health and Consumer Affairs Council Meeting. Brussels, 7 December 2012. http://www.consilium.europa.eu/uedocs/cms_data/ docs/pressdata/en/lsa/134097pdf December 2012. Date last accessed: January 12, 2014.
- 28 Bousquet J, Tanasescu C, Camuzat T, *et al.* Impact of early diagnosis and control of chronic respiratory diseases on active and healthy ageing. A debate at the European Union Parliament. *Allergy* 2013; 68: 555–561.
- 29 Bousquet J, Anto JM, Sterk PJ, *et al.* Systems medicine and integrated care to combat chronic noncommunicable diseases. *Genome Med* 2011; 3: 43.
- 30 Yanbaeva DG, Dentener MA, Creutzberg EC, et al. Systemic effects of smoking. Chest 2007; 131: 1557–1566.
- Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. *J Appl Physiol* 2005; 98: 1154–1162.
 European Union/Innovation Union. Consultation on the Pilot European Innovation Partnership on Active and Healthy Ageing. http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing January 2014. Date last accessed: January 12, 2014.
- 33 Campbell H, Hotchkiss R, Bradshaw N, et al. Integrated care pathways. BMJ 1998; 316: 133–137.
- 34 Overill S. A practical guide to care pathways. J Integr Care 1998; 2: 93–98.
- 35 Great Ormond Street Hospital for Children NHS Trust. How to Produce and Evaluate an Integrated Care Pathway (ICP): Information for Staff. London, Great Ormond Street Hospital for Children NHS Trust, 2010. Available from: www.gosh.nhs.uk/health-professionals/integrated-care-pathways/
- 36 Integrated Care Pathways Users in Scotland (ICPUS). A Workbook for People Starting to Develop Integrated Care Pathways. ICPUS, 2007. Available from: www.icpus.org.uk/wp-content/uploads/2007/08/icpus_workbook_2007.pdf

- 37 Campbell SM, Reeves D, Kontopantelis E, *et al.* Effects of pay for performance on the quality of primary care in England. *N Engl J Med* 2009; 361: 368–378.
- 38 Kirschner K, Braspenning J, Akkermans RP, *et al.* Assessment of a pay-for-performance program in primary care designed by target users. *Fam Pract* 2013; 30: 161–171.
- 39 Rodriguez HP, Perry L, Conrad DA, et al. The reliability of medical group performance measurement in a single insurer's pay for performance program. Med Care 2012; 50: 117–123.
- 40 Pinnock H, Burton C, Campbell S, *et al.* Clinical implications of the Royal College of Physicians three questions in routine asthma care: a real-life validation study. *Prim Care Respir J* 2012; 21: 288–294.
- 41 Ouwens M, Hulscher M, Hermens R, *et al.* Implementation of integrated care for patients with cancer: a systematic review of interventions and effects. *Int J Qual Health Care* 2009; 21: 137–144.
- 42 Chan R, Webster J. End-of-life care pathways for improving outcomes in caring for the dying. *Cochrane Database Syst Rev* 2010; CD008006.
- 43 Doods S. Designing improved health care processes using discrete event stimulation. Br J Healthcare Comput Inf Manag 2005; 22: 14–16.
- 44 O'Connor J, Seeto C, Saini B, et al. Healthcare professional versus patient goal setting in intermittent allergic rhinitis. Patient Educ Couns 2008; 70: 111–117.
- 45 Lisspers K, Odeback P. Riktlinjer for allergisk rinit och astma maste na ut. Primarvarden och de lokala apoteken behover samarbeta mer [Guidelines for allergic rhinitis and asthma must reach out. Primary health care and the local pharmacies need to cooperate more]. *Lakartidningen* 2012; 109: 615.
- 46 Sullivan PW, Nair KV, Patel BV. The effect of the Rx-to-OTC switch of loratadine and changes in prescription drug benefits on utilization and cost of therapy. *Am J Manag Care* 2005; 11: 374–382.
- 47 European Innovation Partnership on Active and Healthy Ageing. The Specific Actions and How to Engage in their Implementation. http://ec.europa.eu/research/innovation-union/index_en.cfm?section=active-healthy-ageing March 6, 2012. Date last accessed: January 12, 2014.
- 48 World Health Organization Regional Office for Europe. Strategy and Action Plan for Healthy Ageing in Europe, 2012–2020. Copenhagen, World Health Organization Regional Office for Europe, 2012. Available from: www.euro. who.int/__data/assets/pdf_file/0008/175544/RC62wd10Rev1-Eng.pdf
- 49 Bousquet J, Mantzouranis E, Cruz AA, et al. Uniform definition of asthma severity, control, and exacerbations: document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 2010; 126: 926–938.
- 50 Bousquet J, Anto JM, Demoly P, *et al.* Severe chronic allergic (and related) diseases: a uniform approach a MeDALL–GA2LEN–ARIA position paper. *Int Arch Allergy Immunol* 2012; 158: 216–231.
- 51 Haahtela T, von Hertzen L, Makela M, *et al.* Finnish Allergy Programme 2008–2018 time to act and change the course. *Allergy* 2008; 63: 634–645.
- 52 International Primary Care Respiratory Group. Mapping of National Guidelines used by Primary Care. www. theipcrg.org/display/ResMapping/Mapping+of+national+guidelines+used+by+primary+care July 2013. Date last accessed: January 12, 2014.
- 53 Council of the European Union. Council Conclusions: Innovative Approaches for Chronic Diseases in Public Health and Healthcare Systems. 3053rd Employment, Social Policy Health and Consumer Affairs Council Meeting, Brussels, 7 December 2010. www.consilium.europa.eu/uedocs/cms_data/docs/pressdata/en/lsa/118282.pdf December 2010. Date last accessed: January 12, 2014.
- 54 Bousquet J, Clark TJ, Hurd S, et al. GINA guidelines on asthma and beyond. Allergy 2007; 62: 102–112.
- 55 Bel EH, Sousa A, Fleming L, *et al.* Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI). *Thorax* 2011; 66: 910–917.
- 56 National Heart, Lung and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Bethesda, US Department of Health and Human Services, 2007.
- 57 Hamrock E, Paige K, Parks J, *et al.* Discrete event simulation for healthcare organizations: a tool for decision making. *J Healthc Manag* 2013; 58: 110–124.
- 58 Bolton P, Power P. Better than a crystal ball? Using simulation to foresee emerging issues in the Australian Healthcare System. *World Hosp Health Serv* 2011; 47: 31–33.
- 59 Lee BY, Wong KF, Bartsch SM, *et al.* The Regional Healthcare Ecosystem Analyst (RHEA): a simulation modeling tool to assist infectious disease control in a health system. *J Am Med Inform Assoc* 2013; 20: e139–e146.
- 60 Murray RE, Ryan PB, Reisinger SJ. Design and validation of a data simulation model for longitudinal healthcare data. *AMIA Annu Symp Proc* 2011; 1176–1185.
- 61 Borycki EM, Kushniruk A, Keay E, *et al.* Toward an integrated simulation approach for predicting and preventing technology-induced errors in healthcare: implications for healthcare decision-makers. *Healthc Q* 2009; 12: 90–96.
- 62 Pidaparti RM, Koombua K. Simulation of the effect of airway disease on respiratory airways. *J Med Eng Technol* 2012; 36: 338–343.
- 63 Grimaldo F, Orduña JM, Lozano M, *et al.* Towards a simulator of integrated long-term care systems for elderly people. *Int J Artificial Intelligence Tools* 2014; 23: 1440005.
- 64 Barker DJ, Bull AR, Osmond C, *et al.* Fetal and placental size and risk of hypertension in adult life. *BMJ* 1990; 301: 259–262.
- 65 Krauss-Etschmann S, Bush A, Bellusci S, *et al.* Of flies, mice and men: a systematic approach to understanding the early life origins of chronic lung disease. *Thorax* 2013; 68: 380–384.
- Simeoni U, Barker DJ. Offspring of diabetic pregnancy: long-term outcomes. *Sem Fetal Neonat Med* 2009; 14: 119–124.
 Barker DJ. Coronary heart disease: a disorder of growth. *Horm Res* 2003; 59: Suppl. 1, 35–41.
- Barker DJ. Coronary neart disease: a disorder of growth. *Florm Res* 2005; 59: Suppl. 1, 55–41.
 Bousquet J, Jacot W, Yssel H, *et al.* Epigenetic inheritance of fetal genes in allergic asthma. *Allergy* 2004; 59: 138–147.
- Bousquet J, Jacot W, Tsser H, et al. Epigenetic initeritatice of retargeness in ancigar astima. *Party 2004*, 57: 150–147.
 Landrigan PJ, Sonawane B, Butler RN, et al. Early environmental origins of neurodegenerative disease in later life. Environ health Perspect 2005; 113: 1230–1233.